Interim Operational Guidance 

Centers for Disease Control and 

Prevention (CDC)

October 29, 2020

Version 2.0

COVID-19 Vaccination Program 

Jurisdiction Operations

Interim Operational Guidance
COVID-19 VACCINATION PROGRAM 

INTERIM PLAYBOOK FOR JURISDICTION

OPERATIONS – October 29, 2020

2 | Page Version 2.0

Table of Contents

Executive Summary ....................................................................................................................................................5

Section 1: Public Health Preparedness Planning........................................................................................................6

Improvement Planning .......................................................................................................................................6

COVID-19 Vaccination Program Planning ...........................................................................................................6

Section 2: COVID-19 Organizational Structure and Partner Involvement..................................................................8

Planning and Coordination Team (Internal) .......................................................................................................8

State-Local Coordination ....................................................................................................................................8

Tribal Nations and Tribal Communities ..............................................................................................................9

COVID-19 Vaccination Program Implementation Committee (Internal and External).......................................9

Related Guidance and Reference Materials.................................................................................................... 10

Section 3: Phased Approach to COVID-19 Vaccination........................................................................................... 11

Phase 1: Potentially Limited COVID-19 Vaccine Doses Available .................................................................... 12

Phase 2: Large Number of Doses Available; Supply Likely to Meet Demand.................................................. 13

Phase 3: Likely Sufficient Supply...................................................................................................................... 14

Related Guidance and Reference Materials.................................................................................................... 14

Section 4: Critical Populations................................................................................................................................. 15

Identifying and Estimating Critical Populations............................................................................................... 15

Estimating Population Groups for Initial COVID-19 Vaccine Distribution During Phase 1 .............................. 16

Describing and Locating Critical Populations................................................................................................... 16

Related Guidance and Reference Materials.................................................................................................... 17

Section 5: COVID-19 Vaccination Provider Recruitment and Enrollment............................................................... 19

Vaccination Provider Recruitment................................................................................................................... 19

Vaccination Provider Enrollment..................................................................................................................... 21

COVID-19 Vaccination Provider Training ......................................................................................................... 23

Role of Commercial and Federal Partners....................................................................................................... 25

Federal Pharmacy Partnership for COVID-19 Vaccination in Long-Term Care Facilities................................. 26

Federal Direct Allocation to Pharmacy Partners (Phase 2).............................................................................. 26

Related Guidance and Reference Materials.................................................................................................... 26

Section 6: Understanding a Jurisdiction’s COVID-19 Vaccine Administration Capacity.......................................... 27

Related Guidance and Reference Materials.................................................................................................... 28

Section 7: COVID-19 Vaccine Allocation, Ordering, Distribution, and Inventory Management............................. 29
COVID-19 VACCINATION PROGRAM 

INTERIM PLAYBOOK FOR JURISDICTION

OPERATIONS – October 29, 2020

3 | Page Version 2.0

Allocation......................................................................................................................................................... 29

Ordering........................................................................................................................................................... 29

Distribution ...................................................................................................................................................... 30

Inventory Management................................................................................................................................... 31

COVID-19 Vaccine Recovery ............................................................................................................................ 32

Section 8: COVID-19 Vaccine Storage and Handling ............................................................................................... 33

Satellite, Temporary, and Off-Site Clinic Storage and Handling Considerations............................................. 33

Section 9: COVID-19 Vaccine Administration Documentation and Reporting........................................................ 35

Section 10: COVID-19 Vaccination Second-Dose Reminders.................................................................................. 37

Section 11: COVID-19 Requirements for Immunization Information Systems or Other External Systems............ 38

System Infrastructure ...................................................................................................................................... 39

COVID-19 Vaccination Provider Preparation ................................................................................................... 39

Data Management........................................................................................................................................... 39

Ordering and Inventory ................................................................................................................................... 40

Related Guidance and Reference Materials.................................................................................................... 40

Section 12: COVID-19 Vaccination Program Communication................................................................................. 42

COVID-19 Vaccination Communication Objectives......................................................................................... 42

Key Audiences.................................................................................................................................................. 42

Broad Communication Planning Phases.......................................................................................................... 42

Communication Activities................................................................................................................................ 43

Messaging Considerations............................................................................................................................... 43

Communication Channels................................................................................................................................ 44

Partners and Trusted Sources.......................................................................................................................... 44

Crisis and Risk Communication........................................................................................................................ 44

Related Guidance and Reference Materials.................................................................................................... 45

Section 13: Regulatory Considerations for COVID-19 Vaccination ......................................................................... 46

Emergency Use Authorization Fact Sheets...................................................................................................... 46

Vaccine Information Statements..................................................................................................................... 46

Section 14: COVID-19 Vaccine Safety Monitoring................................................................................................... 47

Vaccine Adverse Event Reporting System ....................................................................................................... 47

v-safe................................................................................................................................................................ 47

Vaccine Safety Datalink.................................................................................................................................... 48
COVID-19 VACCINATION PROGRAM 

INTERIM PLAYBOOK FOR JURISDICTION

OPERATIONS – October 29, 2020

4 | Page Version 2.0

Clinical Immunization Safety Assessment Project........................................................................................... 48

Section 15: COVID-19 Vaccination Program Monitoring......................................................................................... 49

CDC Dashboards............................................................................................................................................... 49

Resources......................................................................................................................................................... 49

Messaging ........................................................................................................................................................ 50

Local Jurisdictions............................................................................................................................................ 50

Appendix A: COVID-19 Vaccination Planning Assumptions for Jurisdictions (revised 10/29/2020)....................... 51

Appendix B: COVID-19 Vaccination Scenarios for Jurisdictional Planning—Phase 1, Q4 2020 (updated 

10/29/2020)............................................................................................................................................................. 55

Appendix C: Phase 1 Population Group Worksheet Example ................................................................................. 62

Appendix D: CDC IIS Data Requirements for COVID-19 Vaccine Monitoring.......................................................... 63

Appendix E: Countermeasures Injury Compensation Program............................................................................... 65

Appendix F: Liability Immunity for Covered Persons.............................................................................................. 66

Appendix G: Vaccination Implementation Strategies to Consider for Critical Populations (New) ......................... 68

Appendix H: Pharmacy Partnership for Long-Term Care Program for COVID-19 Vaccination (New)..................... 72

Appendix I: Federal Pharmacy Partnership for COVID-19 Vaccination Program (New) ......................................... 74
COVID-19 VACCINATION PROGRAM 

INTERIM PLAYBOOK FOR JURISDICTION

OPERATIONS – October 29, 2020

5 | Page Version 2.0

Executive Summary

Immunization with a safe and effective COVID-19 vaccine is a critical component of the United States strategy to 

reduce COVID-19-related illnesses, hospitalizations, and deaths and to help restore societal functioning. The goal 

of the U.S. government is to have enough COVID-19 vaccine for all people in the United States who wish to be 

vaccinated. Early in the COVID-19 Vaccination Program, there may be a limited supply of COVID-19 vaccine, and 

vaccination efforts may focus on those critical to the response, providing direct care, and maintaining societal 

function, as well as those at highest risk for developing severe illness from COVID-19.

This document serves as an interim playbook for state, territorial (including the US-affiliated Pacific Islands 

[USAPI] of American Samoa, the Commonwealth of the Northern Mariana Islands, Guam, the Federated States 

of Micronesia, the Republic of the Marshall Islands, and the Republic of Palau), tribal, and local public health 

programs and their partners on how to plan and operationalize a vaccination response to COVID-19 within their 

jurisdictions. The document’s sections cover specific areas of COVID-19 vaccination program planning and 

implementation and provide key guidance documents and links to resources to assist those efforts. Many, but 

not all, of the COVID-19 Vaccination Program activities described may overlap with routine activities; routine 

immunization and pandemic influenza program activities can serve as a foundation for COVID-19 vaccination 

planning. 

Centers for Disease Control and Prevention (CDC) Immunization and Vaccines for Children Cooperative 

Agreement funding recipients (i.e., “awardees”) should use this document to develop and update their COVID19 vaccination plans. Within their vaccination plans, awardees must address all requirements outlined in the 

playbook and clearly describe their responsibility for ensuring activities are implemented. All awardees have 

submitted their interim plans to their CDC project officer.

Information in this interim playbook will be updated as new information (e.g., recommendations for pregnant 

women or pediatric populations) becomes available. 
COVID-19 VACCINATION PROGRAM 

INTERIM PLAYBOOK FOR JURISDICTION

OPERATIONS – October 29, 2020

6 | Page Version 2.0

Section 1: Public Health Preparedness Planning

Pandemic vaccination response planning requires collaboration among a wide range of public- and privatesector partners, including immunization and public health emergency preparedness programs, emergency 

management agencies, healthcare organizations, industry groups that include critical infrastructure sectors, 

policy makers, and community vaccination providers (e.g., pharmacies, occupational health settings, doctors’ 

offices). Many of these partners are engaged regularly in seasonal influenza and other outbreak vaccination 

campaigns, and many served as vaccination providers1 during the 2009 H1N1 pandemic. However, significant 

additional planning is needed to operationalize a vaccination response to COVID-19, which is much larger in 

scope and complexity than seasonal influenza or other previous outbreak-related vaccination responses. 

Following the planning and improvement guidance below can assist in developing a jurisdiction’s baseline 

readiness to launch the COVID-19 Vaccination Program.

Improvement Planning

Improvement planning is the identification of strengths, areas for improvement, and corrective actions that 

results from workshops, exercises, or real-world events. Jurisdictions should use a consistent approach for 

improvement-related activities across each of their COVID-19 vaccination preparedness planning components. 

Gaps in program planning are often identified when plans are tested, whether through a real event, such as a 

hepatitis A outbreak, or a full-scale vaccination exercise. Jurisdictions should test their COVID-19 vaccination 

program plans, and after testing, assign roles and responsibilities with target completion dates for specific tasks 

to ensure that corrective actions are fully implemented. Periodic review and revision of plans are integral to the 

improvement process. Jurisdictions should support continuous quality improvement as they move through 

different phases of workshops, exercises, and actual COVID-19 vaccination program implementation, making 

and operationalizing improvements in an ongoing manner.

COVID-19 Vaccination Program Planning

Prior to plan development, it is important for jurisdictions to have full situational awareness. There are many 

unknowns and unanswered questions at this time. For example, it is not yet known which vaccines will be 

available, in what volumes, at what time, with what efficacy, and with what storage and handling requirements. 

However, jurisdictions should review all current planning assumptions to assist with early planning efforts. (See 

Appendix A: COVID-19 Vaccination Planning Assumptions for Jurisdictions.)

In addition to current situational awareness, there is much to learn from past experiences. Jurisdictions may find 

it helpful to review their 2009 H1N1 pandemic vaccination response plans and lessons learned. After-action 

reports and improvement plans from that time provide an opportunity for jurisdictions to build on prior 

strengths and determine any gaps that may need to be addressed. 

After plans have been drafted, it is important to identify any weaknesses by conducting exercises, including

workshops or tabletop, functional, or full-scale exercises. This may be particularly valuable for any activities 

planned with external partners. For example, vaccination clinics in temporary or off-site settings, such as those 

planned for essential workers, are an excellent opportunity for exercises. Specific procedures to assess could 

1 For the purposes of this document, “vaccination provider” refers to any facility, organization, or healthcare provider 

licensed to possess/administer vaccine or provide vaccination services. A “COVID-19 vaccination provider” is any 

vaccination provider who has been enrolled in the COVID-19 Vaccination Program.
COVID-19 VACCINATION PROGRAM 

INTERIM PLAYBOOK FOR JURISDICTION

OPERATIONS – October 29, 2020

7 | Page Version 2.0

include cold chain management, vaccine administration and documentation, traffic flow, or social distancing and 

sanitation measures. The Federal Emergency Management Agency (FEMA) has posted information on its

Homeland Security Exercise and Evaluation program that jurisdictions may find useful as they plan their own 

exercises. 
COVID-19 VACCINATION PROGRAM 

INTERIM PLAYBOOK FOR JURISDICTION

OPERATIONS – October 29, 2020

8 | Page Version 2.0

Section 2: COVID-19 Organizational Structure and Partner 

Involvement

Pandemic vaccination planning is a combined state, territorial, tribal, and local responsibility that requires close 

collaboration between public health, external agencies, and community partners. Depending on the specific 

jurisdiction’s governance structure, the jurisdiction may play a key role in ensuring readiness at all levels. It is 

imperative that state and local jurisdictions, tribal nations, and their planning partners clearly understand each 

other’s roles and responsibilities in the COVID-19 Vaccination Program.

Planning and Coordination Team (Internal)

An internal COVID-19 Vaccination Program planning and coordination team is critical to ensure the vaccination 

response to COVID-19 is thoughtfully planned and successfully executed. A wide array of expertise should be 

represented among team members. Jurisdictions should consider broad inclusion from the immunization 

program, preparedness program, legal affairs, media/public affairs, and crisis and emergency risk 

communication (see Section 12: COVID-19 Vaccination Program Communication for additional information on 

crisis communication planning). In addition, the team should include clinical expertise as well as representatives 

of programs that serve the early populations of focus (e.g., Bureau of Aging, state licensing board, HIV/AIDS 

program, rural health office). It may even be helpful to include representation from a local public health 

jurisdiction for implementation perspective. Team members should be assigned responsibilities based on their 

individual expertise to best enhance plan development and activities coordination before and during the 

response. To mitigate any unexpected situations affecting a team member, each team member should have a 

backup representative to ensure coverage of each specialty area remains intact throughout the COVID-19 

Vaccination Program. For any roles that are not adequately staffed, efforts should be made to recruit for and fill 

any team member vacancies as early as possible.

State-Local Coordination

State governance structures vary from centralized to decentralized. In a centralized state, legal authority is 

concentrated in the central state government, which makes decisions and performs most functions. Conversely, 

in a decentralized state, authority and responsibilities are dispersed and distributed across regions and areas.

Regardless of the jurisdiction’s governance structure, it is imperative that state and local authorities combine

and coordinate efforts. State-level personnel must closely monitor activities at the local level to ensure the 

COVID-19 Vaccination Program is implemented throughout the jurisdiction in adherence with federal guidance 

and requirements, and that there is equitable access to COVID-19 vaccination across all areas. Local personnel

likely have a better understanding of perceptions, unique challenges, and successful mitigation strategies within 

their communities. Aligning areas of responsibility as well as specific tasks can help to complement rather than 

duplicate efforts at either level, maximizing the efficient use of resources and overall quality of the COVID-19 

Vaccination Program. 
COVID-19 VACCINATION PROGRAM 

INTERIM PLAYBOOK FOR JURISDICTION

OPERATIONS – October 29, 2020

9 | Page Version 2.0

Tribal Nations and Tribal Communities

While engaging with tribal leaders, jurisdictional2 immunization programs must remember each tribal nation has 

the sovereign authority to provide for the welfare of its people and, therefore, has the authority to:

• Choose among the jurisdiction or Indian Health Service (IHS) options for accessing vaccine.

• Determine the population(s) it chooses to serve.

• Choose how vaccines are distributed to its community.

• Establish priority groups when there is a limited supply of COVID-19 vaccine or other accompanying 

resources.

For the COVID-19 Vaccination Program, tribal nations have two options for receiving vaccine:

1. Through the jurisdiction’s allocation and distribution mechanism

2. Through the IHS allocation and distribution mechanism

State and local jurisdictions do not possess legal authority over tribal nations directly providing vaccine to their 

service populations. However, if a tribal nation or any of the health facilities serving that tribal nation receive 

vaccine from the jurisdiction’s allocation, they are responsible for adhering to vaccine storage, handling, 

distribution, and reporting requirements outlined in the CDC COVID-19 Vaccination Program Provider 

Agreement.

Jurisdictions should reach out to tribal nations within their respective areas for involvement in planning efforts. 

Jurisdictions must include each tribe’s preference for COVID-19 vaccine distribution to ensure vaccine is 

effectively delivered to tribal nations and their communities. State and local jurisdictions should also engage 

with Urban Indian Health Centers (UIHCs). IHS may be able to support distribution to UIHCs and is planning to 

formally confer with UHICs to solicit their feedback. Additionally, awardee jurisdictions should reach out to 

UIHCs as part of the planning process to determine their preference for vaccine access. Details of engagement

with tribal nations and other tribal entities should be included in jurisdiction COVID-19 vaccination plans.

The jurisdictional planning process should include state-recognized tribes, unrecognized tribes, and American 

Indian/Alaska Native individuals who are included in state-recognized tribes because the option to access

COVID-19 vaccine through IHS may not be possible for these communities.

COVID-19 Vaccination Program Implementation Committee (Internal and External)

Reaching intended vaccine recipients is essential to achieving desired levels of COVID-19 vaccination coverage. 

To ensure equitable access to vaccinations, information about populations within a jurisdiction and the logistical 

requirements for providing them access to COVID-19 vaccination services will require collaboration with external

entities and community partners who are familiar with how they obtain healthcare and other essential services. 

Jurisdictions should establish a COVID-19 Vaccination Program implementation committee to enhance 

development of plans, reach of activities, and risk/crisis response communication messaging and delivery. 

Committee membership should include leadership from the jurisdiction’s COVID-19 planning and coordination 

team as well as representatives from key COVID-19 vaccination providers for critical population groups 

2 “Jurisdiction/jurisdictional,” as used in this document, refers to the federal immunization funding awardees described in 

the Executive Summary and their state public health emergency preparedness counterparts who are tasked with 

developing COVID-19 vaccination plans for submission to CDC. 
COVID-19 VACCINATION PROGRAM 

INTERIM PLAYBOOK FOR JURISDICTION

OPERATIONS – October 29, 2020

10 | Page Version 2.0

identified by CDC (see Section 4: Critical Populations), as well as representatives from other sectors within the 

community, such as:

• Emergency management agencies

• Healthcare coalitions 

• Immunization coalitions

• Local health departments 

• Health systems and hospitals (including critical access hospitals for rural areas, in-patient psychiatric 

facilities) 

• Community health centers

• Rural Health Clinics (RHCs)

• Pharmacies

• Long-term care facilities (LTCFs; includes nursing homes/skilled nursing facilities, assisted living facilities, 

intermediate care facilities for individuals with intellectual and developmental disabilities, and 

independent/retirement communities

• Businesses and occupational health organizations

• Health insurance issuers and plans

• Education agencies and providers

• Correctional facilities

• Churches or religious leaders and institutions

• Tribal leaders

• Organizations serving racial and ethnic minority groups

• Organizations serving people with disabilities

• Organizations serving people with limited English proficiency

• Community representatives

• Entities involved in COVID-19 testing center organization

This committee will be helpful in advocating for and developing strategies to ensure equitable access to COVID19 vaccination services. If needed, a Memorandum of Understanding (MOU) between the jurisdiction and 

partners can help to cement roles, responsibilities, and the level of support to be provided. 

Related Guidance and Reference Materials

CDC’s public health preparedness resources can assist jurisdictions and tribal organizations with strategic 

planning to strengthen their public health capabilities. 

Pandemic influenza-specific resources on vaccine and other medical countermeasures may be helpful in 

strategizing for other COVID-19-related situations. 
COVID-19 VACCINATION PROGRAM 

INTERIM PLAYBOOK FOR JURISDICTION

OPERATIONS – October 29, 2020

11 | Page Version 2.0

Section 3: Phased Approach to COVID-19 Vaccination

Due to changing vaccine supply levels at various points during the COVID-19 Vaccination Program, planning 

needs to be flexible but as specific as possible to accommodate a variety of scenarios. A key point to consider is 

that vaccine supply will be limited at the beginning of the program, so the allocation of doses must focus on 

vaccination providers and settings for vaccination of limited critical populations as well as outreach to these 

populations. The vaccine supply is projected to increase quickly over the proceeding months, allowing 

vaccination efforts to be expanded to additional critical populations and the general public. It is important to 

note that recommendations on the various population groups to receive initial doses of vaccine could change 

after vaccine is available, depending on each vaccine’s characteristics, vaccine supply, disease epidemiology, and 

local community factors.

Final decisions are being made about use of initially available supplies of COVID-19 vaccines. These decisions will 

be partially informed by the proven efficacy of the vaccines coming out of Phase 3 trials, but populations of 

focus for initial COVID-19 vaccination may include: (see Section 4: Critical Populations) 

• Healthcare personnel (paid and unpaid persons serving in healthcare settings who have the potential for 

direct or indirect exposure to patients or infectious materials) 

• Non-healthcare essential workers

• Adults with high-risk medical conditions who possess risk factors for severe COVID-19 illness

• People 65 years of age and older (including those living in LTCFs)

Jurisdictions should be planning in terms of three phases: 

1. Phase 1: Potentially limited supply of COVID-19 vaccine doses available

o Concentrate efforts on reaching the initial populations of focus for COVID-19 vaccination listed 

above, including those who may be part of other critical populations that might require 

additional vaccination efforts to ensure access to vaccine. Ensure vaccination locations selected 

can reach populations, manage cold chain requirements, and meet reporting requirements for 

vaccine supply and uptake. 

2. Phase 2: Large number of vaccine doses available 

o Focus on ensuring access to vaccine for all critical populations who were not vaccinated in Phase 

1, as well as for the general population; expand provider network. 

3. Phase 3: Sufficient supply of vaccine doses for entire population (surplus of doses)

o Focus on ensuring equitable vaccination access across the entire population. Monitor vaccine 

uptake and coverage; reassess strategy to increase uptake in populations or communities with 

low coverage.

The following graph illustrates the three phases of the COVID-19 Vaccine Program and populations of focus in 

each phase.
COVID-19 VACCINATION PROGRAM 

INTERIM PLAYBOOK FOR JURISDICTION

OPERATIONS – October 29, 2020

12 | Page Version 2.0

 *Planning should consider that there may be initial age restrictions for vaccine products.

 **See Section 4: Critical Populations for information on Phase 1 subset and other critical population groups.

Phase 1: Potentially Limited COVID-19 Vaccine Doses Available

In the initial phase, or Phase 1, of the COVID-19 Vaccination Program, initial doses of vaccine will likely be

distributed in a limited manner, with the goal of maximizing vaccine acceptance and public health protection 

while minimizing waste and inefficiency. The key considerations in planning for this phase are:

• COVID-19 vaccine supply may be limited.

• COVID-19 vaccine administration efforts must concentrate on the initial populations of focus to achieve

vaccination coverage in those groups. 

• Inventory, distribution, and any repositioning of vaccine will be closely monitored through reporting to 

ensure end-to-end visibility of vaccine doses.

Jurisdictions can employ strategies to address these constraints, including: 

• Concentrating early COVID-19 vaccine administration efforts on the initial critical populations identified 

above and in Section 4: Critical Populations.

• Providing COVID-19 vaccination services in closed point-of-dispensing (POD) settings that allow for the 

maximum number of people to be vaccinated while maintaining social distancing and other infection 

control procedures (e.g., large hospitals and satellite, temporary, or off-site settings)
COVID-19 VACCINATION PROGRAM 

INTERIM PLAYBOOK FOR JURISDICTION

OPERATIONS – October 29, 2020

13 | Page Version 2.0

Jurisdictions should prioritize enrollment activities for vaccination providers and settings who will administer 

COVID-19 vaccine to the populations of focus for Phase 1, considering those who live in remote, rural areas and 

may have difficulty accessing vaccination services. Simultaneously, jurisdictions should develop operational 

procedures for any temporary or mobile clinics planned for Phase 1 prior to receipt of vaccine. Additional 

information on COVID-19 vaccination provider outreach and clinic settings is located in Section 5: COVID-19 

Provider Recruitment and Enrollment.

Three scenarios are provided in Appendix B: COVID-19 Vaccination Scenarios for Jurisdictional Planning – Phase 

1, Q4 2020 to assist with planning for Phase 1. Each hypothetical scenario presents variations in product 

availability, number of vaccine doses allocated, storage and handling requirements, and administration by 

theoretical vaccine product. These three scenarios may be especially helpful in conducting any workshops or 

exercises.

As jurisdictions are performing Phase 1 activities, they should be thinking ahead to Phase 2. Jurisdictions may 

consider the need for additional vaccinators to staff PODs, contract needs for vaccination services, and 

reviewing state practice acts to allow for expanded professional practice, if necessary.

Phase 2: Large Number of Doses Available; Supply Likely to Meet Demand

As the supply of available vaccine increases, distribution will expand, increasing access to vaccination services 

for a larger population. When larger quantities of vaccine become available, there will be two simultaneous 

objectives:

1. Provide equitable access to COVID-19 vaccination for all critical populations to achieve high COVID-19 

vaccination coverage in these populations in the jurisdiction.

2. Ensure high uptake in specific populations, particularly in groups that are higher risk for severe 

outcomes from COVID-19.

The key considerations in planning for Phase 2 are:

• COVID-19 vaccine supply will likely be sufficient to meet demand for critical populations as well as the 

general public.

• Additional COVID-19 vaccine doses available will permit an increase in vaccination providers and 

locations.

• A surge in COVID-19 vaccine demand is possible, so a broad vaccine administration network for surge 

capacity will be necessary.

• Low COVID-19 vaccine demand is also a possibility, so jurisdictions should monitor supply and adjust 

strategies to minimize vaccine wastage.

Jurisdictions should adapt to the increase in COVID-19 vaccine supply levels by:

• Expanding vaccination efforts beyond initial population groups in Phase 1 with emphasis on equitable 

access for all populations.

• Administering vaccine through:

o Commercial and private sector partners (pharmacies, doctors’ offices, clinics)

o Public health sites (mobile clinics, Federally Qualified Health Centers [FQHCs], RHCs, public 

health clinics, temporary/off-site clinics, and federal, tribal, and Urban Indian health facilities)
COVID-19 VACCINATION PROGRAM 

INTERIM PLAYBOOK FOR JURISDICTION

OPERATIONS – October 29, 2020

14 | Page Version 2.0

Phase 3: Likely Sufficient Supply

Ultimately, COVID-19 vaccine will be widely available and integrated into routine vaccination programs, run by 

both public and private partners.

The key considerations in planning for Phase 3 are:

• Likely sufficient COVID-19 vaccine supply where supply might exceed demand

• Broad vaccine administration network for increased access 

Strategies that jurisdictions should consider:

• Continuing to focus on equitable vaccination access to vaccination services

• Monitoring COVID-19 vaccine uptake and coverage in critical populations and enhancing strategies to 

reach populations with low vaccination uptake or coverage

• Partnering with commercial and private entities to ensure COVID-19 vaccine and vaccination services 

are widely available

• Monitoring supply and repositioning refrigerated vaccine products to minimize vaccine wastage

Related Guidance and Reference Materials 

CDC’s Roadmap to Implementing Pandemic Influenza Vaccination of Critical Workforce provides additional 

information and tools for state and local planners on how to operationalize and implement specific plans for 

targeting critical workforce groups during an influenza pandemic response. The document also includes tools 

and resources for tracking progress on critical workforce vaccination planning and activities within a jurisdiction.

Though currently specific to an influenza pandemic, it may help to inform the approach for COVID-19 

vaccination planning for critical workforce.
COVID-19 VACCINATION PROGRAM 

INTERIM PLAYBOOK FOR JURISDICTION

OPERATIONS – October 29, 2020

15 | Page Version 2.0

Section 4: Critical Populations

CDC’s Advisory Committee on Immunization Practices (ACIP), the National Institutes of Health, and the National 

Academies of Sciences, Engineering, and Medicine (NASEM) are working to determine populations of focus for 

COVID-19 vaccination and ensure equity in access to COVID-19 vaccination availability across the United States. 

CDC has established an ACIP work group to review evidence on COVID-19 epidemiology and burden as well as 

COVID-19 vaccine safety, vaccine efficacy, evidence quality, and implementation issues to inform 

recommendations for COVID-19 vaccination policy. A key policy goal is to determine critical populations for 

COVID-19 vaccination, including those groups identified to receive the first available doses of COVID-19 vaccine 

when supply is expected to be limited.

After a short period of potentially limited vaccine supply, supply will likely increase quickly, allowing vaccination 

efforts to be expanded to include additional critical populations as well as the general public. Jurisdictions 

should develop plans to ensure equitable access to vaccination for each of the critical populations identified 

below.

Identifying and Estimating Critical Populations

The first step in planning is to identify and estimate the critical populations within a jurisdiction. These 

populations (listed in no particular order) may include but are not limited to: 

• Critical infrastructure workforce

o Healthcare personnel (i.e., paid and unpaid personnel working in healthcare settings, which may 

include vaccinators, pharmacy staff, ancillary staff, school nurses, and EMS personnel) 

o Other essential workers (see additional guidance from the Cybersecurity and Infrastructure 

Security Agency [CISA])

Note: The critical infrastructure workforce varies by jurisdiction. Each jurisdiction must decide which

groups to focus on when vaccine supply is limited by determining key sectors that may be within 

their populations (e.g., port-related workers in coastal jurisdictions)

• People at increased risk for severe COVID-19 illness

o

o

o

o

o

o

o

o

o

o

o

o

LTCF residents (i.e., residents of nursing homes and assisted living facilities) 

People with underlying medical conditions that are risk factors for severe COVID-19 illness

o People 65 years of age and older

• People at increased risk of acquiring or transmitting COVID-19

People from racial and ethnic minority groups

People from tribal communities

People who are incarcerated/detained in correctional facilities

People experiencing homelessness/living in shelters

People attending colleges/universities

People who work in educational settings (e.g., early learning centers, schools, and 

colleges/universities)

People living and working in other congregate settings

• People with limited access to routine vaccination services

People living in rural communities

People with disabilities

People who are under- or uninsured
COVID-19 VACCINATION PROGRAM 

INTERIM PLAYBOOK FOR JURISDICTION

OPERATIONS – October 29, 2020

16 | Page Version 2.0

Estimates of these groups should be as accurate as possible to minimize potential waste of vaccine, constituent 

products, or ancillary supplies. Partner agencies and organizations may be helpful in determining accurate 

estimates of these population groups. Such organizations might include the jurisdiction’s emergency 

management agency, labor department, chamber of commerce, healthcare coalitions, and chronic 

disease/nutrition groups, as well as the U.S. Department of the Interior, federal executive boards, and the 

Association of Continuity Professionals. 

Estimating Population Groups for Initial COVID-19 Vaccine Distribution During Phase 1

In the event that the jurisdiction’s allocation during Phase 1 is insufficient to vaccinate all those included in the 

initial populations of focus, it is important for jurisdictions to identify and estimate the subset groups (i.e., Phase 

1-A, Phase 1-B) within these initial populations of focus to determine who will receive the first available doses of 

COVID-19 vaccine. Jurisdictions can review current ACIP work group considerations for assistance in identifying, 

prioritizing, and estimating Phase 1 sub-population groups. 

Jurisdictional considerations for Phase 1 subset groups may include, for example: 

 Phase 1-A: Paid and unpaid persons serving in healthcare settings who have the potential for direct or 

indirect exposure to patients or infectious materials 

 Phase 1-B: People who play a key role in keeping essential functions of society running and cannot 

socially distance in the workplace (e.g., emergency and law enforcement personnel not included in

Phase 1-A, food packaging and distribution workers, teachers/school staff, childcare providers), adults 

with high-risk medical conditions who possess risk factors for severe COVID-19 illness, and people 65 

years of age or older (including those living in LTCFs)

There may be insufficient COVID-19 vaccine supply initially to vaccinate all those who fall into the Phase 1-A 

subset, so jurisdictions should plan for additional subsets within that group (see CISA guidance for categories 

of healthcare personnel). Phase 1-B and Phase 2 planning may also benefit from identifying subsets of 

population groups if there is high demand for vaccine. The U.S. Department of Labor’s Occupational Safety 

and Health Administration has information on classifying workers at risk (low to very high based on position 

within an organization) for exposure to SARS-CoV-2. This information could prove helpful to jurisdictions in 

determining subsets of critical populations for vaccination. 

Describing and Locating Critical Populations

To improve vaccination among critical population groups, jurisdictions must ensure these groups have access to 

vaccination services. To inform COVID-19 vaccination provider outreach efforts, jurisdictions need to know 

where these groups are located. Jurisdictions should create visual maps of these populations, including places of 

employment for the critical infrastructure workforce category, to assist in COVID-19 vaccination clinic planning, 

especially for satellite, temporary, or off-site clinics. Certain jurisdictions have critical infrastructure workforces, 

such as healthcare personnel, that cross jurisdictional boundaries to get to their workplaces. Rather than try to 

enumerate these populations by place of residence, jurisdictions should consider enumeration by place of 

employment. Enumeration by health system to estimate its workforce may include both inpatient and 

outpatient facilities as well as any satellite clinics. The shift between daytime and nighttime essential worker 

populations is most pronounced in the mid- and northeastern jurisdictions. Accounting for workers by place of 

employment will help to minimize underestimation of these critical populations. The convenience of receiving 

vaccination at the place of employment may also result in increased vaccination coverage. Public health 
COVID-19 VACCINATION PROGRAM 

INTERIM PLAYBOOK FOR JURISDICTION

OPERATIONS – October 29, 2020

17 | Page Version 2.0

programs should establish procedures to communicate key messages and coordinate vaccination logistics for 

these groups.

Programs should establish points of contact (POCs) for each organization, employer, or community (as 

appropriate) within the critical population groups. Partnerships with trusted community organizations can 

facilitate early agreement on communication channels and methods for rapidly disseminating information and 

ultimately ensuring these groups have access to vaccination. (See Section 12: COVID-19 Vaccination Program 

Communication.) Some of these partners could include: 

• Community health centers

• FQHCs

• RHCs

• Critical access hospitals

• Pharmacies

• Organizations and businesses that employ critical workforce

• First responder organizations

• Tribal health or community centers

• Non-traditional providers (e.g., community health workers, doulas, promotoras) and locations (e.g., 

dialysis centers, community centers) serving people at higher risk for severe illness

• Other locations or facilities for shared or congregate housing serving people at higher risk for COVID-19 

illness (e.g., homeless shelters, group housing, correctional facilities, senior living facilities)

• Locations where people 65 years of age and older gather (e.g., senior centers, food pantries)

• Religious groups and other community groups

• In-home care organizations

• Schools and institutions of higher learning

Additional strategies for jurisdictions to consider when planning to vaccinate critical populations are listed in 

Appendix G: Vaccination Implementation Strategies to Consider for Critical Populations.

Jurisdictions should prioritize describing and locating the Phase 1 initial populations of focus (see above) in their 

planning efforts, as these groups will be the first to be vaccinated before other critical populations.

A sample worksheet for collecting critical population POCs and other pertinent information is in Appendix C: 

Phase 1 Population Group Worksheet Example.

Related Guidance and Reference Materials

Advisory Committee on Immunization Practices

NASEM Preliminary Framework for Equitable Allocation of COVID-19 Vaccine

Johns Hopkins Center for Health Security Interim Framework for COVID-19 Vaccine Allocation and Distribution in 

the United States

The HHS Office for Civil Rights (OCR) webpage on Civil Rights and COVID-19 has several resources, including: 

• BULLETIN: Civil Rights, HIPAA, and the Coronavirus Disease 2019 (COVID-19)

• BULLETIN: Ensuring the Rights of Persons with Limited English Proficiency in Health Care During COVID19
COVID-19 VACCINATION PROGRAM 

INTERIM PLAYBOOK FOR JURISDICTION

OPERATIONS – October 29, 2020

18 | Page Version 2.0

• BULLETIN: Civil Rights Protections Prohibiting Race, Color, and National Origin Discrimination During 

COVID-19: Application of Title VI of the Civil Rights Act of 1964

• Information on the resolution of complaints filed with HHS OCR such as those that allege age and 

disability discrimination due to a state’s crisis standards of care guidelines, etc.

Mapping Medicare Disparities Tool can be used to identify areas of disparities between subgroups of Medicare 

beneficiaries in health outcomes, utilization, and spending. It can assist with investigating geographic and racial 

and ethnic differences in health outcomes and inform decisions to focus on certain populations and 

geographies. 
COVID-19 VACCINATION PROGRAM 

INTERIM PLAYBOOK FOR JURISDICTION

OPERATIONS – October 29, 2020

19 | Page Version 2.0

Section 5: COVID-19 Vaccination Provider Recruitment and 

Enrollment

An adequate network of trained, technically competent COVID-19 vaccination providers in accessible settings is 

critical to COVID-19 Vaccination Program success. For this reason, COVID-19 vaccination provider recruitment 

and enrollment may be the most critical activity conducted before vaccine becomes available. Jurisdictions and 

tribal organizations should concentrate early planning efforts on engaging those vaccination providers and 

services that can rapidly vaccinate initial populations of focus (see Section 4: Critical Populations) as soon as a 

COVID-19 vaccine is available (Phase 1). Subsequent planning should include measures for recruiting and 

enrolling enough providers to vaccinate additional critical populations and eventually the general population 

when sufficient vaccine supply is available (Phases 2 and 3).

Vaccination Provider Recruitment

Jurisdictions are encouraged to immediately reach out to potential COVID-19 vaccination providers and target 

the appropriate settings so that COVID-19 vaccination services are accessible to the initial populations of focus 

when the first COVID-19 vaccine doses arrive. Providers and settings that maximize the number of people who 

can be vaccinated should be prioritized for enrollment; however, jurisdictions should ensure social distancing 

and other infection control procedures can be maintained in selected settings (see CDC guidance on vaccination 

during a pandemic). All providers/settings, especially those enrolled for Phase 1, must be able to meet the 

reporting requirements discussed in Section 9: COVID-19 Vaccine Administration Documentation and Reporting

and Section 11: COVID-19 Requirements for Immunization Information Systems or Other External Systems. 

Jurisdictions should consider partnering with the private sector and with local hospitals or health systems to 

provide COVID-19 vaccination in the closest proximity possible to the initial populations of focus. For example, 

partnering with critical access hospitals will be key to vaccinating Phase 1 populations in rural areas. Suggested 

early COVID-19 vaccination providers/settings include:

• Large hospitals and health systems

• Commercial partners* (e.g., pharmacies)

• Mobile vaccination providers

• Occupational health settings for large employers

• Critical access hospitals, RHCs, community health centers, or other central locations that can provide 

vaccination services for a broad area

*CDC has agreements with CVS and Walgreens to assist with on-site vaccination in LTCFs. These 

partners have existing distribution (including cold chain), administration, and reporting infrastructure 

and relationships with some LTCFs to provide medication and, in some cases, vaccination services (e.g., 

seasonal influenza) for staff and residents; this may reduce burden on jurisdictional health departments. 

CDC will ensure jurisdictions have visibility on this work with retail pharmacy partners. 

Jurisdictions should recruit additional COVID-19 vaccination providers to expand equitable access to COVID-19 

vaccination when vaccine supply increases. Enrollment activities should be tracked so vaccination providers are 

not approached multiple times. Establishing and building upon existing relationships with community partners 

and collaborating with medical societies, state licensing boards, the state Medicaid agency, state rural health 

office, IHS/tribal health entities, and health insurance issuers and plans in the area, may assist jurisdictions in 

identifying COVID-19 vaccination providers and the population groups they serve. Jurisdictions should consider 

engaging both traditional and nontraditional vaccination providers and settings, including: 
COVID-19 VACCINATION PROGRAM 

INTERIM PLAYBOOK FOR JURISDICTION

OPERATIONS – October 29, 2020

20 | Page Version 2.0

• In-patient healthcare facilities 

o Large hospitals could potentially operate as open PODs.

• LTCFs (e.g., nursing homes/skilled nursing facilities, assisted living facilities)

• Doctors’ offices and other outpatient facilities (particularly those treating patients at higher risk of 

severe COVID-19 illness)

• Pharmacies

• Occupational health settings

• Organizations serving people at higher risk for severe illness from COVID-19 (e.g., dialysis centers, social 

service organizations)

• In-home care provider organizations

• Congregate settings (e.g., correctional facilities)

• Colleges and universities

• Homeless shelters

• Locations where people 65 years of age and older gather (e.g., senior centers, food pantries, 

retirement/independent living communities)

• FQHCs and RHCs

Jurisdictions and tribal nations should determine the need for additional vaccination services such as satellite, 

temporary, or off-site clinics to meet demand/need not met by other enrolled COVID-19 vaccination providers. 

These clinics may operate as either closed or open PODs. 

It is important to consider infection control measures that are currently necessary when selecting COVID-19 

vaccination clinic settings:

• Providing specific appointment times or other strategies to manage patient flow and avoid crowding and 

long lines.

• Ensuring sufficient staff and resources to help move patients through the clinic flow as quickly as 

possible

• Limiting the overall number of clinic attendees at any given time, particularly for people at higher risk 

for severe illness from COVID-19

• Setting up a unidirectional site flow with signs, ropes, or other measures to direct site traffic and ensure 

physical distancing between patients

• When feasible, arranging a separate vaccination area or separate hours for people at increased risk for 

severe illness from COVID-19, such as older adults and people with underlying medical conditions

• Making available a point of contact for any reasonable accommodation needs for people with disabilities

• Ensuring vaccination locations are accessible to individuals with disabilities consistent with disability 

rights statutes such as the Americans with Disabilities Act and Section 504 of the Rehabilitation Act of 

1973

• Selecting a space large enough to ensure a minimum distance of 6 feet between patients in line or in 

waiting areas for vaccination, between vaccination stations, and in postvaccination monitoring areas.

Note: ACIP recommends that providers consider observing patients for 15 minutes after vaccination to 

decrease the risk for injury should they faint. For mobile or drive-through vaccination clinics, it is 

important to assess parking to accommodate vaccine recipients as they wait after vaccination.
COVID-19 VACCINATION PROGRAM 

INTERIM PLAYBOOK FOR JURISDICTION

OPERATIONS – October 29, 2020

21 | Page Version 2.0

Vaccination Provider Enrollment

To receive/administer COVID-19 vaccine, constituent products, and ancillary supplies, vaccination provider

facilities/organizations must enroll in the federal COVID-19 Vaccination Program coordinated through their 

jurisdiction’s immunization program. Enrolled COVID-19 vaccination providers must be credentialed/licensed in 

the jurisdiction where vaccination takes place, and sign and agree to the conditions in the CDC COVID-19 

Vaccination Program Provider Agreement. These conditions are detailed in the agreement itself:

1. Administer COVID-19 vaccine in accordance with ACIP recommendations. (Note: ACIP will review data 

on the safety and efficacy of each available COVID-19 vaccine and vote on recommendations for use.)

2. Within 24 hours of administering a dose of COVID-19 vaccine and adjuvant (if applicable), record in the 

vaccine recipient’s record and report required information to the relevant state, local, or territorial 

public health authority. (See Appendix D: CDC IIS Data Requirements for COVID-19 Vaccine Monitoring). 

The provider must maintain the vaccine administration records for at least 3 years following vaccination, 

or longer if required by state, local, or territorial law. These records must be made available to any 

federal, state, local, or territorial public health department to the extent authorized by law.

3. Not sell or seek reimbursement for COVID-19 Vaccine and any diluent, syringes, needles, or other 

constituent products and ancillary supplies provided by the federal government.

4. Administer COVID-19 vaccine regardless of the vaccine recipient’s ability to pay.

5. Provide an Emergency Use Authorization (EUA) fact sheet for recipients or vaccine information 

statement (VIS), as applicable, to each vaccine recipient/parent/legal representative prior to 

vaccination.

6. Comply with CDC requirements for vaccine management, including storage and handling, temperature 

monitoring at all times, complying with jurisdiction’s instructions for dealing with temperature 

excursions, and monitoring expiration dates. Providers must keep all records related to COVID-19 

vaccine management for a minimum of 3 years, or longer if required by law.

7. Report COVID-19 vaccines and diluents that were unused, spoiled, expired, or wasted as required by the 

jurisdiction’s immunization program.

8. Comply with federal instruction regarding disposal of unused COVID-19 vaccine and diluent.

9. Report vaccine administration errors (whether associated with an adverse event [AE]) or not, serious 

AEs (irrespective of attribution to vaccination),

3 multisystem inflammatory syndrome (MIS) in children 

or adults, and cases of COVID-19 that result in hospitalization or death to the Vaccine Adverse Event 

Reporting System (VAERS). Report any additional AEs and adhere to any revised safety reporting 

requirements per the U.S. Food and Drug Administration’s (FDA) conditions of authorized vaccine use 

posted on FDA’s website throughout the duration of the EUA, as applicable. Healthcare providers should 

also report any additional clinically significant adverse events following COVID-19 vaccination to VAERS, 

even if they are not sure if the vaccination caused the event.

10. Provide a completed COVID-19 vaccination record card to every vaccine recipient/parent/legal 

representative.

3 Serious AEs are defined as: death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent 

or significant incapacity or substantial disruption of the ability to conduct normal life functions, a congenital anomaly/birth defect, or an 

important medical event that may not result in death, be life-threatening, or require hospitalization when, based upon appropriate 

medical judgment, it may jeopardize the individual and may require medical or surgical intervention to prevent one of the outcomes 

listed above. Serious AEs should be reported regardless of causality.
COVID-19 VACCINATION PROGRAM 

INTERIM PLAYBOOK FOR JURISDICTION

OPERATIONS – October 29, 2020

22 | Page Version 2.0

11. Comply with FDA’s requirements, including EUA-related requirements described in FDA’s Letter of 

Authorization, as applicable. Providers must also administer COVID-19 vaccine in compliance with all 

applicable state and territorial vaccine laws.

Failure of any enrolled COVID-19 vaccination provider organization or vaccination location under its authority to 

meet the conditions of the agreement may impact whether COVID-19 vaccine product orders are fulfilled and 

may result in legal action by the federal government.

Enrolled COVID-19 vaccination providers must also fully complete the CDC COVID-19 Vaccination Provider Profile

form for each location where COVID-19 vaccine will be administered. The profile form collects the following 

variables for each location:

• Address and contact information

• Days and hours of operation

• Vaccination provider type (e.g., medical practice, pharmacy, LTCF)

• Settings where vaccine will be administered (e.g., hospital, university, temporary or off-site clinic)

• Number of patients/clients served 

• Influenza vaccination capacity during the peak week of the prior (2019–2020) influenza season

• Populations served (e.g., pediatric, adult, military, pregnant women)

• Current IIS reporting status

• Vaccine storage unit capacity in volume and ability to maintain required temperatures

The profile form includes a field where the brand/model/type of storage unit is to be listed, requiring an 

attestation from the medical/pharmacy director or vaccine coordinator that each unit will maintain the relevant 

required temperatures (i.e., refrigerated [2°C to 8°C], frozen [-15° to -25°C], ultra-cold [-60° to -80°C]. If desired, 

the immunization program may request photos of vaccine storage units for confirmation.

Both forms (agreement and profile) may be submitted to the jurisdiction electronically, and it is permissible for 

an immunization program to develop and administer these forms in the IIS or other system.

Note: A vaccine coordinator is the POC for receiving vaccine shipments, monitoring storage unit temperatures, 

managing vaccine inventory, etc. Immunization programs should encourage enrolled facilities/organizations to 

designate a vaccine coordinator role at each location as well as a back-up vaccine coordinator.

Provider enrollment activities that immunization programs must complete include:

• Ensure provider agreement, profile form, and redistribution agreement (if applicable) are thoroughly

and accurately completed by each enrolled provider, retained on file for a minimum of 3 years, and 

made available to CDC upon request

• Verify COVID-19 vaccination providers) have active, valid licensure/credentials to possess and 

administer vaccine. This licensure verification is needed only for those with prescribing authority [e.g., 

MD, DO, RPh, NP, PA] who will oversee COVID-19 vaccine administration. Credential verification is not 

required for vaccinators who work under the authority of someone with a higher level of licensure (i.e., 

not required for pharmacy techs/interns, RNs, LPNs, medical assistants, etc.).

• Onboard COVID-19 vaccination providers to the jurisdiction’s IIS or other external system using an 

expedited process. 

• Enter ship-to site information for each enrolled COVID-19 vaccination provider location in the Vaccine 

Tracking System (VTrckS) via direct upload or extensible XML information set (ExIS). (Note: To support 
COVID-19 VACCINATION PROGRAM 

INTERIM PLAYBOOK FOR JURISDICTION

OPERATIONS – October 29, 2020

23 | Page Version 2.0

more efficient distribution of vaccine, locations should offer full-day receiving hours to the extent 

possible. When that is not possible, COVID-19 vaccination providers must be available to receive vaccine 

shipments during a 4-hour window on a weekday other than Monday.)

• Report COVID-19 vaccination provider enrollment data electronically to CDC twice a week (i.e., Monday 

and Thursday by 9:00pm EST), using CDC-provided Comma Separated Values (CSV) and JavaScript Object 

Notation (JSON) templates to report via a Security Access Management Services (SAMS)–authenticated 

mechanism. CDC will monitor provider enrollment progress (see Section 15: COVID-19 Vaccination 

Program Monitoring).

• Ensure that all COVID-19 vaccination providers have been trained appropriately and have the 

appropriate equipment at their location to manage any serious adverse events. (Note: For new 

vaccination providers and nontraditional provider settings, it will be helpful to furnish vaccination clinic 

planning guidance to ensure optimum staffing, layout, supplies, and infection control procedures are in 

place.)

COVID-19 Vaccination Provider Training

Training of COVID-19 vaccination providers is vital to ensure the success of the COVID-19 Vaccination Program. 

CDC will have many educational resources available for use (even some for co-branding), but immunization 

programs may develop or use other materials in conjunction with CDC materials. Jurisdictions should determine 

the most efficient methods for training delivery and tracking. Online videos may be particularly useful for 

convenient access and standardization of instruction. Jurisdictions will not be required to provide training for 

federal entities and commercial partners receiving direct vaccine allocations from CDC.

COVID-19 vaccination providers must understand the following:

• ACIP COVID-19 vaccine recommendations, when available

• How to order and receive COVID-19 vaccine

• COVID-19 vaccine storage and handling (including transport requirements) 

• How to administer vaccine, including mixing with diluent, appropriate needle size, anatomic sites for 

vaccine administration, avoiding shoulder injury with vaccine administration, etc.

• How to document and report vaccine administration via the jurisdiction’s IIS or other external system

• How to manage vaccine inventory, including accessing and managing product expiration dates (see 

Section 7: COVID-19 Vaccine Allocation, Ordering, Distribution, and Inventory Management)

• How to report vaccine inventory 

• How to manage temperature excursions

• How to document and report vaccine wastage/spoilage

• Procedures for reporting adverse events as well as vaccine administration errors to VAERS

• Providing EUA fact sheets or VISs to vaccine recipients

• How to submit facility information and daily vaccine inventory reports for COVID-19 vaccination clinics 

to CDC’s VaccineFinder (particularly for pharmacies or other high-volume vaccination providers/settings)

CDC is developing and updating a variety of clinical educational and training resources for healthcare 

professionals related to COVID-19 vaccine(s). Some of these materials will soon be available to assist with 

planning for vaccine implementation. Other materials will become available as regulatory authorization or 

approval from FDA for each vaccine candidate is acquired. Each manufacturer is also developing educational and 

training resources for its individual vaccine candidate. The list may change or be updated as appropriate. 
COVID-19 VACCINATION PROGRAM 

INTERIM PLAYBOOK FOR JURISDICTION

OPERATIONS – October 29, 2020

24 | Page Version 2.0

PRODUCT NEW/UPDATE ADDITIONAL INFORMATION

Vaccine Storage and Handling 

Toolkit

Update An addendum with general COVID-19 vaccine storage, 

handling and transport information will be added, and 

the addendum will be updated as COVID-19 vaccine 

products are approved. A fully updated toolkit, 

incorporating COVID-19 information into the actual 

toolkit will not be issued until 2022.

COVID-19 training module New Under development is a web-based module. Topics 

will include storage/handing, vaccine indications, 

contraindications/precautions, administration, and 

documentation. It will not have CE and will be 

amended as new COVID-19 vaccine products are 

introduced.

Vaccine product summary sheets New Fact sheets with storage, handling, preparation, 

indications, contraindications/precautions, and 

administration will be developed for each vaccine

Additional immunization guidance 

materials

New More extensive information related to storage, 

handling, preparation, administration, shipping, 

packaging, and transport will be provided as necessary 

(not all vaccines will need additional guidance)

Comprehensive table of vaccine 

products

New A table of COVID-19 vaccine products with key 

information will be updated as vaccines are approved.

Beyond use dates and expiration 

date tracking tools

New A resource will be provided to track BUD and 

expiration dates, for use early in vaccine distribution 

process.

ACIP recommendation summary 

information

New Conduct webinar, slide deck for use by awardees and 

other partners

You Call the Shots web-based 

Training

Update Updates to the You Call the Shots Vaccine 

Administration and Storage and Handling modules to 

refer users to appropriate COVID-19 vaccine websites. 

Information will be updated more extensively in early 

2021 based on continuing education timelines.

Healthcare personnel FAQs New Web-based FAQ document

Providing vaccinations 

Safely during a pandemic

Update CDC has developed this website to provide guidance 

about safely providing vaccines during COVID 19. The 

website will be updated as appropriate.
COVID-19 VACCINATION PROGRAM 

INTERIM PLAYBOOK FOR JURISDICTION

OPERATIONS – October 29, 2020

25 | Page Version 2.0

Role of Commercial and Federal Partners

Some multijurisdictional vaccination providers (e.g., select large drugstore chains, some IHS locations, Veterans 

Administration clinics and hospitals, and other federal providers) will enroll directly with CDC to order and 

receive COVID-19 vaccine. CDC will notify jurisdictions of any entities receiving direct allocations within their 

areas. These direct partners will be required to report vaccine supply and uptake information to each respective 

jurisdiction. Jurisdictions may partner with commercial entities that are enrolled directly with CDC to reach their 

populations. Large drugstore chains, for example, may be particularly helpful in conducting PODs as well as

vaccinating LTCF residents and staff. Health insurance issuers and plans may also assist in informing their 

enrollees about vaccination efforts. 

Federal Direct Allocation to Federal Entities

Outlined below are the federal entities (and their respective populations) that will receive a direct allocation of 

COVID-19 vaccine. 

Federal Entity Population Served

Bureau of Prisons (BoP) • All BoP-managed facilities: facility staff and inmates

• Private contracted facilities and contracted residential reentry centers 

(RRCs) not included

Department of Defense (DoD) • Active duty personnel and their dependents

• Retirees (does not include their dependents)

• U.S. Coast Guard (does not include their dependents)

• DoD civilian and contractor employees (those who regularly receive 

care through DoD as well as those who don’t)

• To be determined: Reserves and National Guard (including those not 

activated)

Department of State (DoS) • All personnel under Chief of Mission eligible to receive care through 

DoS

• Stateside civil service employees

Indian Health Service (IHS) • Tribal nations selecting IHS for vaccine allocation (see page 12: Tribal 

Nations and Tribal Communities)

• Potentially includes IHS/Tribal/Urban facility staff and individuals served

Veterans Health Administration 

(VHA)

• VA staff (including volunteers and trainees) and veterans regularly 

receiving care at VHA facilities

(State Veterans Homes not included)
COVID-19 VACCINATION PROGRAM 

INTERIM PLAYBOOK FOR JURISDICTION

OPERATIONS – October 29, 2020

26 | Page Version 2.0

Federal Pharmacy Partnership for COVID-19 Vaccination in Long-Term Care Facilities

CDC will collaborate with CVS and Walgreens to provide on-site vaccination clinics for LTCF residents. CDC is

working closely with LTCFs, jurisdictions, Centers for Medicare and Medicaid Services (CMS), professional trade 

organizations that serve nursing homes and assisted living facilities, and pharmacy partners to inform facilities of 

their options to receive COVID-19 vaccine. Depending on when LTCF staff is prioritized to receive vaccine, they 

will be covered under this plan (if prioritized at the same time as residents) or covered under jurisdiction plans 

for vaccinating healthcare workers/essential populations (if prioritized before residents). If staff is prioritized 

before residents, any staff not already vaccinated may be vaccinated through the on-site clinics offered by 

pharmacy partners. (See Appendix H: Pharmacy Partnership for Long-Term Care Program for COVID-19 

Vaccination.) 

Federal Direct Allocation to Pharmacy Partners (Phase 2)

To vaccinate a broader population group in Phase 2, vaccine will be allocated and distributed directly from the 

federal government to select pharmacy partners. Direct allocation opportunities will be provided to retail chain 

pharmacies and networks of independent and community pharmacies4 (those with a minimum of 200 stores). 

All partners must sign a pharmacy provider agreement with the federal government. As part of such agreement, 

before receiving COVID-19 vaccine, the partner must propose, in writing, its minimum capacity for vaccine 

administration, including a) the number and location of facilities that will administer COVID-19 vaccine, b) the 

estimated number of COVID-19 vaccine doses that each facility will be able to administer within defined periods, 

and c) estimated cold chain storage capacity. 

On a daily basis, pharmacy partners must report to CDC via designated methods the number of doses of COVID19 vaccine a) ordered by store location; and b) on hand in each store reported through VaccineFinder. Pharmacy 

providers will also be required to report CDC-defined data elements related to vaccine administration to 

jurisdiction IISs. CDC will provide information on these data elements and reporting methods if stores are not 

able to directly provide data to jurisdiction IISs. 

Partnerships with pharmacies will need to be synchronized with jurisdictions to improve vaccination coverage 

and ensure transparency across the COVID-19 Vaccination Program. Jurisdictions will be provided an 

opportunity to opt out of having pharmacies in their area receive direct allocations. Once a jurisdiction opts out, 

it will not be able to opt back into the program. All jurisdictions participating in this program will have visibility 

on vaccine supply and uptake data by store within their respective areas. (See Appendix I: Federal Pharmacy 

Partnership Strategy for COVID-19 Vaccination Program.)

Related Guidance and Reference Materials

HHS authorization for state-licensed pharmacists to administer vaccines

4 Pharmacy services administrative organizations, or PSAOs
COVID-19 VACCINATION PROGRAM 

INTERIM PLAYBOOK FOR JURISDICTION

OPERATIONS – October 29, 2020

27 | Page Version 2.0

Section 6: Understanding a Jurisdiction’s COVID-19 Vaccine 

Administration Capacity

Occupational health settings, temporary vaccination clinics, 

and closed PODs may be particularly useful for vaccination 

of critical infrastructure workers and other select critical 

populations early in the COVID-19 vaccination response 

when vaccine supply may be limited. However, once vaccine 

supply increases, leveraging a wide variety of potential 

community COVID-19 vaccination providers and settings is 

essential to providing equitable access to COVID-19 

vaccination for all people in all communities. Public health 

programs should understand their jurisdiction’s overall 

potential COVID-19 vaccine administration capacity, using a 

variety of COVID-19 vaccination provider types and settings. 

“Vaccine administration capacity” is defined as the 

maximum achievable vaccination throughput regardless of 

public demand for vaccination. If a jurisdiction has a good 

understanding of its COVID-19 vaccination providers and 

locations and their vaccine administration capacities, then 

planners can generate rough estimates of COVID-19 vaccine 

administration capacity in their jurisdiction and their ability to reach various COVID-19 vaccination coverage 

goals.

Important elements to consider in estimating vaccination capacity: 

• Estimated number of existing vaccination provider locations in the jurisdiction, by type or vaccination 

setting, and the populations served (e.g., adults, children) 

• Estimated potential weekly COVID-19 vaccine administration capacity (throughput) 

• Estimated vaccination provider participation rate in the COVID-19 Vaccination Program 

When assessing vaccine administration capacity, other important factors to consider include:

• COVID-19 vaccine storage capacity at a given location (e.g., quantity of COVID-19 vaccine that can be 

stored, storage equipment and temperature monitoring devices that meet CDC requirements)

• Existing vaccine administration capacity during seasonal influenza or other high vaccination periods

• Current staffing levels

• Routine immunization programs being conducted simultaneously that may affect throughput for COVID19 vaccination in certain vaccination provider settings

• Infection control measures (i.e., scheduling, distancing, donning and doffing personal protective 

equipment, cleaning/sanitation procedures) that may slow the vaccination process

• Timing and duration of COVID-19 vaccination provider participation due to changes in staffing or other 

resources throughout the response

• Clinic closure due to environmental or other factors (e.g., seasonal weather, wildfires, holidays)

Box 1: Key Public and Private Sector 

Vaccination Settings

• Healthcare provider offices and 

other outpatient clinics

• Public health clinics

• Chain and independent 

pharmacies

• School-based health centers

• Worksites and other occupational 

health clinics

• Hospitals 

• Temporary or off-site vaccination 

clinics* 

• Mobile vaccinators

*Community locations where state and local 

agencies dispense and administer medical 

countermeasures [MCMs] to the public, also known 

as “points of dispensing” [PODs])
COVID-19 VACCINATION PROGRAM 

INTERIM PLAYBOOK FOR JURISDICTION

OPERATIONS – October 29, 2020

28 | Page Version 2.0

Jurisdictions should seek input from a variety of COVID-19 vaccination providers to inform this process. Previous 

vaccination exercises or campaigns may also provide helpful information. 

Related Guidance and Reference Materials

CDC has developed a tool to assist with estimating vaccination capacity. The newest version of this tool, the 

PanVax Tool for Pandemic Vaccination Planning (version 3.3), is available on the CDC website. 
COVID-19 VACCINATION PROGRAM 

INTERIM PLAYBOOK FOR JURISDICTION

OPERATIONS – October 29, 2020

29 | Page Version 2.0

Section 7: COVID-19 Vaccine Allocation, Ordering, 

Distribution, and Inventory Management

Initial supplies of COVID-19 vaccine may be available in fall 2020. Early dose distribution will be limited; 

therefore, phased allocation of early vaccine doses will likely be necessary. Populations of focus for initial 

COVID-19 vaccine doses are expected to include healthcare workers (including ancillary staff, vaccinators, and

staff in LTCFs), other essential workers, and people at higher risk for severe COVID-19 illness 5

. See Section 4: 

Critical Populations for more information. Jurisdictions should anticipate allocations to shift during the response 

based on supply, demand, vaccine characteristics, and disease epidemiology and should plan for high-demand 

and low-demand scenarios. 

Allocation

The federal government will determine the amount of COVID-19 vaccine designated for each jurisdiction. The 

jurisdiction’s immunization program will then be responsible for managing and approving orders from enrolled 

providers within their jurisdiction using this allotment. The amount allotted will change over time, which may be 

based on critical populations recommended for vaccination by ACIP (with input from NASEM), COVID-19 vaccine 

production and availability, and overall population of the jurisdiction. 

Federal agencies and additional commercial partners will also receive allocations directly from CDC once larger 

volumes of vaccine are available. CDC is currently developing procedures to ensure that jurisdictions have full 

visibility of COVID-19 vaccine supply and vaccination activities among these entities located within their 

boundaries.

Immunization programs should develop allocation methods for critical populations of focus in early- and limitedsupply scenarios. Prior to receiving an initial vaccine supply, jurisdictions should determine COVID-19 vaccine

order allowances among their vaccination providers based on the critical populations they serve. Allotments of 

doses to vaccination providers within a jurisdiction should be based on:

• ACIP recommendations (when available)

• Estimated number of doses allocated to the jurisdiction and timing of availability

• Populations served by vaccination providers and geographic location to ensure distribution throughout 

the jurisdiction

• Vaccination provider site vaccine storage and handling capacity

• Minimizing the potential for wastage of vaccine, constituent products, and ancillary supplies 

• Other local factors

See Section 4: Critical Populations for more information.

Ordering

COVID-19 vaccination providers enrolled by the jurisdiction will order COVID-19 vaccine through their 

jurisdiction’s immunization program. Most jurisdictions will ask COVID-19 vaccination providers to place orders 

using systems and procedures routinely used for ordering publicly funded vaccines (e.g., IIS/ExIS upload to CDC’s 

VTrckS for provider direct order entry), though some jurisdictions may have augmented systems. 

5 Subject to any vaccine product-specific age restrictions
COVID-19 VACCINATION PROGRAM 

INTERIM PLAYBOOK FOR JURISDICTION

OPERATIONS – October 29, 2020

30 | Page Version 2.0

CDC will provide jurisdictions with regular updates on the available vaccine supply and their assigned vaccine

product-specific allocations in VTrckS. During Phase 1 of the vaccination program, when there is limited vaccine 

supply for critical populations, immunization programs should approve orders based on the likely populations 

served by a vaccination provider, the provider’s capability to store and handle various COVID-19 vaccine 

products, and existing inventory. The minimum order size and increment for centrally distributed vaccines will 

be 100 doses per order; though early in the response, ultra-cold (-60°C to -80°C) vaccine (if authorized for use or 

approved) may be shipped directly from the manufacturer in 975-dose increments. CDC will share more 

information on these shipments as it becomes available. 

Ancillary supplies will be packaged in kits and will be automatically ordered in amounts to match vaccine orders 

in VTrckS. 

A. For centrally distributed vaccines, each kit will contain supplies to administer 100 doses of vaccine, 

including: 

• Needles, 105 per kit (various sizes for the population served by the ordering vaccination provider) 

o 25-gauge, 1” (if vaccination indicated for pediatric population) 

o 22–25-gauge, 1-1.5” (adult) 

• Syringes, 105 per kit (ranging from 1–3 mL) 

• Alcohol prep pads, 210 per kit 

• 4 surgical masks and 2 face shields for vaccinators per kit

• COVID-19 vaccination record cards for vaccine recipients, 100 per kit

• Vaccine needle guide detailing the appropriate length/gauge for injections based on route, age (for 

children), gender, and weight (for adults)

If a COVID-19 vaccine that requires mixing with diluent is ordered and shipped from CDC’s centralized 

distributor, a mixing kit that includes the necessary needles, syringes, and alcohol prep pads will also be 

automatically added to the order. For centrally distributed vaccines, providers will have the option to 

submit the order in a way that opts out of receiving the administration and mixing kits. 

B. For vaccines that are shipped directly from the manufacturer, a combined kit will be included. This 

combined kit will include administration supplies (as noted above), mixing supplies, and vials of diluent

to prepare the vaccine for use. Because it contains diluent, providers will not have the option to opt out 

of requesting this combined ancillary kit.

Ancillary supply kits will not include sharps containers, gloves, and bandages. Additional personal protective 

equipment (PPE) may be needed depending on vaccination provider site needs. 

Facilities ordering outside of their jurisdiction’s allocation (i.e., commercial and federal entities with federal 

MOUs in place) will order directly from CDC, and CDC will be responsible for approval of those orders. 

Distribution

COVID-19 vaccines and ancillary supplies will be procured and distributed by the federal government at no cost 

to enrolled COVID-19 vaccination providers. CDC will use its centralized distribution contract to fulfill orders for 

most vaccine products and associated ancillary supplies. Some vaccine products, such as those with ultra-cold 

temperature requirements, will be shipped directly from the manufacturer to the vaccination provider site.

Jurisdictions should ensure accurate and complete shipping information (e.g., shipment address, provider 

contact information, shipping hours) is available in VTrckS for all vaccine shipments to enrolled vaccination 
COVID-19 VACCINATION PROGRAM 

INTERIM PLAYBOOK FOR JURISDICTION

OPERATIONS – October 29, 2020

31 | Page Version 2.0

providers. To support more efficient distribution of vaccine, locations should offer full-day receiving hours to the 

extent possible. When that is not possible, locations identified to receive vaccine and ancillary supply shipments 

must be available during a 4-hour window on a weekday other than Monday to receive those shipments.

COVID-19 vaccine (and diluent, if required) will be shipped to vaccination provider sites enrolled by the 

jurisdiction’s immunization program within 48 hours of order approval. Because of cold chain requirements, 

ancillary supply kits (and diluent, if applicable) will ship separately from vaccine but should arrive before or on 

the same day as vaccine. 

The federally contracted vaccine distributor uses validated shipping procedures to maintain COVID-19 vaccine 

cold chain and minimize the likelihood of vaccine loss or damage during shipment. Once a vaccine product has 

been shipped to a COVID-19 vaccination provider site, the federal government will neither redistribute the 

product nor take financial responsibility for its redistribution. (See Section 8: COVID-19 Vaccine Storage and 

Handling for more information.) 

Whenever possible, vaccine should be shipped to the location where it will be administered to minimize 

potential breaks in the cold chain. However, there may be circumstances where COVID-19 vaccine needs to be 

redistributed beyond the identified primary CDC ship-to sites (i.e., for orders smaller than the minimum order 

size or for large organizations whose vaccine is shipped to a central depot and requires redistribution to 

additional clinic locations). In these instances, vaccination provider organizations/facilities, third-party vendors, 

and other vaccination providers may be allowed, if approved by the jurisdiction’s immunization program, to 

redistribute COVID-19 vaccine, if validated cold-chain procedures are in place in accordance with the 

manufacturer's instructions and CDC’s guidance on COVID-19 vaccine storage and handling. These entities must 

sign and agree to conditions in the CDC COVID-19 Vaccine Redistribution Agreement for the sending 

facility/organization and have a fully completed and signed CDC COVID-19 Vaccination Provider Profile form for 

each receiving location. Jurisdictions should be extremely judicious in allowing redistribution and limit any 

redistribution to refrigerated vaccines only. 

Immunization programs may occasionally allow local transport of vaccines from one location to another within 

their jurisdictions, if adherence to cold chain and tracking requirements are maintained. CDC does not pay for or 

reimburse jurisdictions, COVID-19 vaccination provider organizations, facilities, or other entities for any 

redistribution beyond the initial designated primary CDC ship-to location, or for any vaccine-specific portable 

refrigerators and/or qualified containers and pack-outs. (See Section 8: COVID-19 Vaccine Storage and Handling

for more information.) 

Inventory Management

COVID-19 vaccination providers will be required to report COVID-19 vaccine inventory daily using 

VaccineFinder. Once providers are enrolled in VTrckS, they will be preregistered for a VaccineFinder account and 

provided instructions via email on how to submit daily supply information. Jurisdictions may also require that 

providers submit inventory on hand when placing an order for more vaccine to help inform their allocation 

decisions. However, submission of this information into VTrckS is optional. All inventory should be managed in 

accordance with storage and handling requirements specific to each vaccine. 

It is anticipated that COVID-19 vaccines will initially be authorized under an EUA. Vial and carton labels for 

vaccines authorized under an EUA will contain slight variations from labels typical of approved Food and Drug 

Administration (FDA) products, including: 
COVID-19 VACCINATION PROGRAM 

INTERIM PLAYBOOK FOR JURISDICTION

OPERATIONS – October 29, 2020

32 | Page Version 2.0

• Expiration Date: The vaccine vials and cartons may not contain a printed expiration date. Expiration 

dates may be updated based on vaccine stability studies occurring simultaneously with COVID-19 

vaccine distribution and administration. Additional information will be provided about how to access 

expiry information for individual vaccines. To ensure that information systems continue to work as 

expected, CDC has worked with FDA and the manufacturers to include a two-dimensional (2D) barcode 

on the vaccine vial (if possible) and carton (required) labels that includes a National Drug Code (NDC), lot

number, and a placeholder expiration date of 12/31/2069 to be read by a scanner. The placeholder 

12/31/2069 expiration date is not visible on the vaccine packaging nor found anywhere else; it is only to 

facilitate information system compatibility. CDC is developing “beyond use date” (BUD) tracker labels to 

assist clinicians with tracking expiration dates at the point of vaccine administration. The label templates

will be available on the CDC website.

• Manufactured Date: A manufactured date will be on the packaging and should not be used as the 

expiration date when documenting vaccine administration. This date is provided to help with managing 

stock rotations; however, expiration dates should also be considered (see above) as using manufactured 

date alone could have some limitations. 

• 2D Barcode: The 2D barcode available on the vaccine carton (also on the vials for some vaccines) will

include NDC, lot number, and a placeholder expiration date of 12/31/2069. 

• QR Code: Each vaccine manufacturer will include a Quick Response (QR) code on the vaccine carton for 

accessing FDA-authorized, vaccine product-specific EUA fact sheets for COVID-19 vaccination providers 

and COVID-19 vaccine recipients.

A list of authorized COVID-19 vaccine products with corresponding EUA fact sheets for healthcare providers and 

vaccine recipients, and up-to-date expiration information by vaccine lot will be available on an HHS website.

COVID-19 Vaccine Recovery

Details of COVID-19 vaccine recovery are still being finalized and will be communicated when available. 
COVID-19 VACCINATION PROGRAM 

INTERIM PLAYBOOK FOR JURISDICTION

OPERATIONS – October 29, 2020

33 | Page Version 2.0

Section 8: COVID-19 Vaccine Storage and Handling

COVID-19 vaccine products are temperature-sensitive and must be stored and handled correctly to ensure 

efficacy and maximize shelf life. Proper storage and handling practices are critical to minimize vaccine loss and 

limit risk of administering COVID-19 vaccine with reduced effectiveness. Jurisdictions should work with staff at 

each COVID-19 vaccination provider site to ensure appropriate vaccine storage and handling procedures are 

established and followed.

It is expected that cold chain storage and handling requirements for COVID-19 vaccine products will vary in 

temperature from refrigerated (2°C to 8°C) to frozen (-15°C to -25°C) to ultra-cold (-60°C to -80°C) in the freezer 

or within the dry ice thermal shipper in which product was received. Ongoing stability testing may impact these 

requirements. Note: These temperatures are based on information available as of 10/29/2020. Updated 

information will be provided as it becomes available. 

For a reliable cold chain, three elements must be in place: 

• Well-trained staff

• Reliable storage and temperature monitoring equipment

• Accurate vaccine inventory management

The cold chain begins at the COVID-19 vaccine manufacturing plant, includes delivery to and storage at the 

COVID-19 vaccination provider site, and ends with administration of COVID-19 vaccine to a person. Jurisdictions 

and vaccination providers are responsible for maintaining vaccine quality from the time a shipment arrives at a 

vaccination provider site until the dose is administered. To minimize opportunities for breaks in the cold chain, 

most COVID-19 vaccine will be delivered from CDC’s centralized distributor directly to the location where the 

vaccine will be stored and administered, although some vaccine may be delivered to secondary depots for 

redistribution. Certain COVID-19 vaccine products, such as those with ultra-cold temperature requirements, will 

be shipped directly from the manufacturer to the vaccination provider site. If redistributing vaccine, jurisdictions 

must adhere to all cold chain requirements and should limit transport of frozen or ultra-cold vaccine products.

Every vaccine storage unit/container must have a temperature monitoring device. CDC recommends digital data 

loggers (DDLs). One vaccine product is stored at ultra-cold temperatures and will require a DDL that can register

these temperatures. CDC is currently exploring options to support acquisition of DDLs for use with ultra-cold 

vaccines. However, jurisdictions should continue to identify options to obtain DDLs for use with ultra-cold 

vaccines, in addition to the DDLs needed for storage of refrigerated and frozen (-20°C) vaccines. DDLs using a 

buffered temperature probe provide the most accurate measurement of vaccine temperatures. However, many 

manufacturers use pure propylene glycol (freezing point -59°C) or a glycol mixture with a warmer freezing point 

in their probes. For accurate temperature monitoring of ultra-cold vaccines, it is essential that an air-probe or a 

probe designed specifically for ultra-cold temperatures is used with the DDL. 

An addendum to the Vaccine Storage and Handling Toolkit that specifically addresses COVID-19 vaccines is 

currently being developed in addition to other training materials. 

Satellite, Temporary, and Off-Site Clinic Storage and Handling Considerations

Satellite, temporary, or off-site clinics in collaboration with community or mobile vaccinators may assist 

jurisdictions in providing equitable access for COVID-19 vaccination. However, these situations require 

additional oversight and enhanced storage and handling practices, including:
COVID-19 VACCINATION PROGRAM 

INTERIM PLAYBOOK FOR JURISDICTION

OPERATIONS – October 29, 2020

34 | Page Version 2.0

• The quantity of COVID-19 vaccine transported to a satellite, temporary, or off-site COVID-19 vaccination 

clinic should be based on the anticipated number of COVID-19 vaccine recipients and the ability of the 

vaccination provider to store, handle, and transport the vaccine appropriately. This is essential to 

minimizing the potential for vaccine wastage and spoilage.

• COVID-19 vaccines may be transported—not shipped—to a satellite, temporary, or off-site COVID-19 

vaccination clinic setting using vaccine transportation procedures outlined in the upcoming COVID-19 

addendum to CDC’s Vaccine Storage and Handling Toolkit. The procedures will include transporting 

vaccines to and from the provider site at appropriate temperatures, using appropriate equipment, as 

well as monitoring and documenting temperatures.

• Upon arrival at the COVID-19 vaccination clinic site, vaccines must be stored correctly to maintain 

appropriate temperature throughout the clinic day.

• Temperature data must be reviewed and documented according to guidance in the upcoming COVID-19 

addendum to CDC’s Vaccine Storage and Handling Toolkit. 

• At the end of the clinic day, temperature data must be assessed prior to returning vaccine to fixed 

storage units to prevent administration of vaccines that may have been compromised.

• As with all vaccines, if COVID-19 vaccines are exposed to temperature excursions6 at any time, the 

temperature excursion should be documented and reported according to the jurisdiction immunization 

program’s procedures. The vaccines that were exposed to out-of-range temperatures must be labeled 

“do not use” and stored at the required temperature until further information on usability can be 

gathered or further instruction on disposition or recovery is received.

Jurisdictions and tribal organizations should review CDC’s revised Guidance for Planning Vaccination Clinics Held 

at Satellite, Temporary, or Off-Site Locations as well as Vaccination Guidance During a Pandemic. These 

resources provide information on additional considerations that are necessary during the COVID-19 pandemic, 

including social distancing, PPE use, and enhanced sanitation efforts.

6 A “temperature excursion” is an event in which the COVID-19 vaccine is exposed to temperatures outside the range(s) 

prescribed for storage and/or transport.
COVID-19 VACCINATION PROGRAM 

INTERIM PLAYBOOK FOR JURISDICTION

OPERATIONS – October 29, 2020

35 | Page Version 2.0

Section 9: COVID-19 Vaccine Administration Documentation 

and Reporting

CDC requires that vaccination providers enrolled in the COVID-19 Vaccination Program report certain data 

elements for each dose administered within 24 hours of administration. (See Appendix D: CDC IIS Data 

Requirements for COVID-19 Vaccine Monitoring). Jurisdictions should assess the capability of COVID-19 

vaccination providers to meet federal and jurisdiction-specific reporting requirements before or upon 

enrollment. The required data elements are located on the ISD Awardees SharePoint site. COVID-19 vaccination 

providers may view the data requirements on CDC’s IIS website. Jurisdictions should be prepared to provide

additional support or technical assistance for smaller vaccination providers or rural clinic settings.

Jurisdictions must facilitate and monitor IIS reporting by enrolled vaccination providers. Each vaccination 

location should be ready (including trained staff, necessary equipment, and internet access) to report vaccine 

administration data to the IIS or other external system at the time of vaccination. If data will be entered off site, 

vaccination providers must ensure the required data are reported to the IIS or other designated system within 

24 hours. Reporting data may be transmitted daily from the jurisdiction’s designated system to the CDC via the 

IZ Gateway7 “Connect” component. Additional information on the reporting process and specifications will be 

shared as soon as they have been finalized. Jurisdictions will not be responsible for reporting data from federal 

agencies or commercial partners who receive vaccine allocations directly from CDC. 

In addition to reporting vaccine administration, jurisdictions must put processes in place to match first and 

second doses including addressing the need to exchange data with or query other jurisdiction’s systems and/or 

the Immunization Data Lake8 to obtain immunization history, if applicable. 

Jurisdictions should ensure redundant measures and procedures are in place for recording vaccine 

administration data in instances of connectivity problems or failures in the jurisdiction’s IIS or other system. The 

jurisdiction’s IIS should collect, report, and submit data directly to CDC’s Immunization Data Lake and 

jurisdictional reporting requirements. (Additional information on CDC data requirements is forthcoming.)

Planning activities should include onboarding to IZ Gateway Connect and Share9 (if feasible) components; 

7 The Immunization Gateway (IZ Gateway) facilitates electronic messaging of vaccination records in a secure infrastructure 

allowing IIS systems across the nation to share vaccine administration data not only between jurisdictions, but also with 

provider organizations (e.g., Department of Defense, Federal Bureau of Prisons, IHS, Department of Veterans Affairs) that 

do not exchange data with the IIS today.

8 The Immunization Data Lake is a cloud-hosted data repository to receive, store, and manage COVID-19 vaccination data 

for doses administered, vaccination coverage, ordering, inventory, and distribution. The Data Lake will provide a catalogue 

of different COVID-19 vaccine-related data sources that can be used to aid in monitoring COVID-19 vaccine ordering, 

distribution, coverage, and uptake. Data streams currently being onboarded to the Data Lake include provider enrollment 

data, VTrckS, and VaccineFinder.

9 There are multiple ways to onboard to the IZ Gateway, including Connect and Share.

• Connect enables large national and non-traditional vaccination systems for satellite/temporary/off-site clinic 

settings to report and query immunization data with IISs, using the gateway’s centralized data exchange, avoiding 

multiple individual, and point-to-point connections. 

• Share allows exchange of immunization data between IIS jurisdictions by automating message triggers through the 
COVID-19 VACCINATION PROGRAM 

INTERIM PLAYBOOK FOR JURISDICTION

OPERATIONS – October 29, 2020

36 | Page Version 2.0

exchanging data with other jurisdictions through the IZ Gateway; generating coverage reports for use within the 

jurisdiction; and providing data to CDC that meet defined standards.

IIS for patients immunized outside of their jurisdiction, to route messages to the patient’s state of residence 

through the IZ Gateway.
COVID-19 VACCINATION PROGRAM 

INTERIM PLAYBOOK FOR JURISDICTION

OPERATIONS – October 29, 2020

37 | Page Version 2.0

Section 10: COVID-19 Vaccination Second-Dose Reminders

For most COVID-19 vaccine products, two doses of vaccine, separated by 21 or 28 days, will be needed. Because 

different COVID-19 vaccine products will not be interchangeable, a vaccine recipient’s second dose must be 

from the same manufacturer as their first dose. Second-dose reminders for vaccine recipients will be critical to 

ensure compliance with vaccine dosing intervals and achieve optimal vaccine effectiveness. COVID-19 

vaccination providers should make every attempt to schedule a patient’s second-dose appointment when they 

get their first dose. 

COVID-19 vaccination record cards will be provided as part of vaccine ancillary kits. Vaccination providers must

complete these cards with accurate vaccine information (i.e., vaccine manufacturer, lot number, date of first 

dose administration, and second dose due date), and give them to each patient who receives vaccine to ensure 

a basic vaccination record is provided. Vaccination providers should encourage vaccine recipients to keep the 

card in case the IIS or other system is not available when they return for their second dose. The card provides 

room for a written reminder for a second-dose appointment. If vaccine recipients have a smartphone, they may 

consider documenting their vaccine administration with a photo of their vaccination record and entering the 

date the next vaccine dose is due on their electronic calendar.

Redundant methods and systems should be used to remind vaccine recipients about their need for second 

doses. Jurisdictions should assess current practices for patient reminder/recall in existing healthcare provider 

organizations. Public health programs should work with occupational health providers and partners to consider 

the most appropriate and effective method of issuing second-dose reminders. A jurisdiction’s IIS can be 

particularly useful for centralized reminder/recall (see Section 11: COVID-19 Requirements for IIS or Other 

External Systems). Many pharmacies and healthcare systems have their own systems for patient notifications 

and reminders, some using functionality within their electronic health record (EHR) systems. Jurisdictions may 

consider exploring the use of automated patient phone calls (“robocalls”), emails, and SMS text message-based 

systems. Health plans may also help to notify their enrollees about second doses based on claims information.
COVID-19 VACCINATION PROGRAM 

INTERIM PLAYBOOK FOR JURISDICTION

OPERATIONS – October 29, 2020

38 | Page Version 2.0

Section 11: COVID-19 Requirements for Immunization 

Information Systems or Other External 

Systems

IISs, also known as “vaccine registries,” are 

confidential, population-based, computerized 

databases for recording information on vaccine doses. 

IISs are maintained by a jurisdiction’s immunization 

program. 

IISs have a range of capabilities. Many IISs can 

exchange data with EHRs, so that documentation of 

vaccine administration is automatically uploaded 

through bidirectional data exchange between EHRs and 

the IIS. EHRs that interface with jurisdiction IISs may

improve the pace and accuracy of vaccine 

administration data capture. Some EHRs may leverage 

2D barcoding technology on vaccine vials and VISs to 

allow for rapid, accurate, and automatic capture of 

vaccine administration data, such as vaccine lot 

number, vaccine manufacturer, and expiration date. In 

many jurisdictions, routine vaccination providers enroll 

in public vaccine programs, order vaccines, report 

inventory, document vaccine spoilage/wastage, and 

remind patients when vaccine doses are due using the IIS. 

Using the IIS to document COVID-19 vaccine dose administration is beneficial on many fronts. When using the 

IIS, vaccination providers are able to determine if a patient is due for the first or second dose of vaccine. This is 

especially helpful in a pandemic situation when people may receive first and second vaccine doses at different 

locations. The IIS will also help to ensure that first and second doses are administered using the same vaccine 

product and appropriately spaced according to ACIP-recommended intervals. Based on a jurisdiction’s discretion 

and IIS functionality, COVID-19 vaccination providers may use IISs to: 

• Preregister or enroll in the COVID-19 vaccination program

• Place orders for COVID-19 vaccine

• Document vaccine administration

• Manage and report vaccine inventory

• Report vaccine spoilage/wastage

• Provide reminders to COVID-19 vaccine recipients indicating when the next dose of a multidose vaccine 

is due 

CDC is making available a vaccination clinic mobile application, Vaccine Administration Management System

(VAMS), that may be used to register patients and record dose-level vaccination data that meets CDC reporting 

requirements. IIS and other external systems that support COVID-19 response efforts must have solid 

Immediate Priorities for Immunization 

Programs Related to Data Reporting:

• Determine and implement a solution for 

documenting vaccine administration in 

temporary or high-volume settings (e.g., 

VAMS or similar application, IIS or module 

that interfaces with the IIS, or other 

jurisdiction-based solution)

• Ensure system capacity for data exchange, 

security, storage, and reporting

• Enroll vaccination provider 

facilities/organizations anticipated to 

vaccinate essential workers

• Connect IIS to the IZ Gateway

• Establish required data use agreements

• Assess and improve data quality

o Ensure data are available, secure, 

complete, timely, valid, accurate, 

consistent, and unique 
COVID-19 VACCINATION PROGRAM 

INTERIM PLAYBOOK FOR JURISDICTION

OPERATIONS – October 29, 2020

39 | Page Version 2.0

infrastructure, engaged partners, high-quality data, and efficient processes for managing vaccination. The 

objectives for these areas are described below. 

System Infrastructure

Jurisdictions should take certain steps to ensure the IIS or other external system’s infrastructure is ready to 

support the COVID-19 Vaccination Program. Each jurisdiction should ensure their IIS infrastructure meets 

COVID-19 response data exchange, storage, and reporting requirements. The hardware and software on which 

the IIS depends should be up to date. For IISs that use a vendor platform, the IIS should be on the latest version 

of the platform. 

The jurisdiction’s IIS must operate as expected to appropriately support COVID-19 vaccination tracking efforts. 

The jurisdiction should prioritize testing and implement fixes for defects and enhancements that impact the IIS’s 

ability to support COVID-19 response efforts.

The jurisdiction must use a system that supports dose-level accountability—from the time vaccine leaves the 

distributor until the vaccine is administered or unused vaccine is returned—and provides data to CDC that meet 

defined standards. Jurisdictions will need to have a solution (either leveraging existing or new) for extracting 

required data from their IIS as a contingency for network outages. The specifications to support the data 

extracts will be provided by CDC to ensure data submissions align with the format required for submission to the 

COVID-19 clearing house (a secure data lake). Jurisdictions should also develop and test backup solutions for 

offline use if the internet is unavailable. 

Jurisdictions should explore and implement available IIS functionality for sending second-dose reminders to 

vaccine recipients via email and/or text messages (see Section 10: COVID-19 Vaccination Second-Dose 

Reminders). This will be critical to ensure recipients complete the COVID-19 vaccine series.

COVID-19 Vaccination Provider Preparation

As jurisdictions enroll providers in the COVID-19 Vaccination Program (see Section 5: COVID-19 Vaccination 

Provider Recruitment and Enrollment), it is critical that they onboard providers to the IIS. Jurisdictions should 

have expedited processes in place to rapidly onboard vaccination providers expected to support Phase 1 

activities and efficient processes to onboard vaccination providers expected to support expanded efforts in 

Phases 2 and 3. 

Jurisdictions may conduct nontraditional COVID-19 vaccination clinics, such as temporary, off-site, or mobile 

vaccination clinics to reach critical populations, particularly during early vaccination efforts. This may require 

jurisdictions to identify, enroll, and train additional partners to report doses administered in the system 

designated to support those efforts.

Data Management

The jurisdiction’s IIS should collect and report data to satisfy CDC and jurisdictional reporting requirements. 

(Additional information on CDC data requirements is forthcoming.) Planning activities should include onboarding 

COVID-19 providers to the IIS, ensuring adequate IIS capacity, and establishing processes to ensure provider 

reporting within 24 hours of administration. IISs should also consider leveraging the IZ Gateway Connect and 

Share (if feasible) components for exchanging data with and/or querying other jurisdictions to obtain a 

consolidated vaccination record; using systems designed to support satellite, temporary, or off-site vaccination 

clinics; and generating coverage reports for use within the jurisdiction. Jurisdictions should be prepared to 
COVID-19 VACCINATION PROGRAM 

INTERIM PLAYBOOK FOR JURISDICTION

OPERATIONS – October 29, 2020

40 | Page Version 2.0

update their Clinical Decision Support (CDS) systems when CDC CDSi (Clinical Decision Support for 

immunizations) resources are updated.

Jurisdictions must have necessary policies in place to facilitate data collection and sharing with CDC and other 

jurisdictions. Jurisdictions onboarding to the IZ Gateway will be required to sign the Data Use Agreement (DUA) 

with Association of Public Health Laboratories (APHL) to participate in both IZ Gateway Connect and IZ Gateway 

Share. Jurisdictions will also need to execute the MOU to share data with other jurisdictions through the IZ 

Gateway.

• APHL – Jurisdiction DUA IZ Gateway (3August2020revision) When executed, the APHL and jurisdiction 

DUA allows for the jurisdiction to participate in the Connect component and to identify which (if any) 

other components to enable (Share, Provider-initiated Multi-jurisdictional Data Exchange, Access and/or 

Access: Consumer-initiated Multi-jurisdictional Data Exchange). This document was updated Aug 3, 2020 

for this expanded use.

• Memorandum of Understanding between Jurisdictions to Exchange Data The Share component 

enables the exchange of immunization information across IIS jurisdictions. To enable the Share 

component, a jurisdiction must execute an Interjurisdictional MOU with jurisdictions with which it will 

exchange data. The MOU allows data exchange to occur through the IZ Gateway or an alternative 

mechanism with any state or jurisdiction that signed the MOU.

Jurisdictions will also need to execute a DUA with CDC so CDC can access their IIS data for national coverage 

data analysis. 

Ordering and Inventory

Jurisdictions must have processes in place for managing and tracking COVID-19 vaccine ordering and inventory. 

Planning activities should include reviewing business processes and IIS functionality to identify and implement 

improvements; developing a plan to order, monitor, and manage COVID-19 vaccine inventory in the IIS using 

CDC standards; and exploring opportunities to adopt 2D barcoding technology to improve data quality. 

Related Guidance and Reference Materials

CDC Vaccination Clinic Mobile Application: Vaccine Administration Management System (VAMS)

• VAMS: An overview of the functionality of the four VAMS modules: IIS jurisdictions, 

employers/organizations, clinics, and vaccine recipients. (Located in SharePoint)

Provider Onboarding

• CDC Provider IIS Participation Community of Practice: An overview of the CDC Provider IIS Participation 

Community of Practice and ideas for addressing important provider IIS participation issues, including 

onboarding, EHR assistance, data quality, and provider training and outreach presented as a webinar on 

April 10, 2019.

• American Immunization Registry Association (AIRA Data Validation Guide – for the IIS Onboarding 

Process (2017): A guide with recommendations on the data validation process within onboarding

• Onboarding Consensus-Based Recommendations (2018): A guide for improving and standardizing 

onboarding intended for technical and programmatic staff that make up IIS onboarding teams and for 

program administrators responsible for allocation of onboarding resources 
COVID-19 VACCINATION PROGRAM 

INTERIM PLAYBOOK FOR JURISDICTION

OPERATIONS – October 29, 2020

41 | Page Version 2.0

Data Quality

• IIS Data Quality Blueprint ― A guide to help immunization program awardees address and advance data 

quality within IISs

• Data Quality Assurance in Immunization Information Systems: Incoming Data (2008): A summary of best 

practice guidelines and immediate actions an IIS can take to improve data quality

• IIS Data Quality Practices to Monitor and Evaluate Data at Rest (2018): Practical guidance on techniques, 

methodologies, and processes for IISs to use in assessing the quality of data at rest, including 

demographic and immunization record information that is currently in the live, production environment 

(e.g., database or other data store). The primary audience for the guide includes IIS managers and staff 

with responsibility for ensuring IIS data quality.

• Consolidating Demographic Records and Vaccination Event Records (2017): Consensus-based best 

practice recommendations to support the process of consolidating demographic and vaccination event 

records.

Immunization Gateway (IZ Gateway)

• Immunization Gateway Information Sheet (Located in SharePoint available to immunization programs)

• Immunization Gateway Overview (Located in SharePoint available to immunization programs)

• Immunization Gateway Q&As for IIS Awardees (Located in SharePoint available to immunization 

programs)

Ordering and Inventory

• Immunization Information System Inventory Management Operations (2012): Consensus-based best 

practice recommendations for IISs to support immunization program requirements for provider 

organizations’ vaccine inventory management and associated IIS reports that support the vaccine 

inventory management needs of provider organizations and grantee immunization programs.

• Decrementing Inventory via Electronic Data Exchange (2016): Consensus-based best practice 

recommendations to support the process of decrementing inventory via electronic data exchange.

• Guidance on Unit of Sale/Unit of Use Lot Numbers (2018): Clarifications to the process and expectations 

for management of vaccine lot numbers.

• Vaccine Code Set Considerations (2020): A general overview of vaccine code sets and brief description of 

how code sets support multiple and varied IIS functions, including electronic data exchange with EHRs 

and other health information systems and vaccine ordering and inventory management.
COVID-19 VACCINATION PROGRAM 

INTERIM PLAYBOOK FOR JURISDICTION

OPERATIONS – October 29, 2020

42 | Page Version 2.0

Section 12: COVID-19 Vaccination Program Communication

Starting before COVID-19 vaccines are available, clear, effective communication will be essential to 

implementing a successful COVID-19 Vaccination Program. Building vaccine confidence broadly and among 

groups anticipated to receive early vaccination, as well as dispelling vaccine misinformation, are critical to 

ensure vaccine uptake. 

A successful COVID-19 Vaccination Program will have lasting effects on the nation’s immunization system and 

overall vaccination efforts in the future. Using risk communication principles along with the CDC’s recently 

developed Vaccinate with Confidence framework, jurisdictions can develop and implement timely, evolving 

plans as the foundation for their overall COVID-19 vaccination communication efforts.

COVID-19 Vaccination Communication Objectives

• Educate the public about the development, authorization, distribution, and execution of COVID-19 

vaccines and that situations are continually evolving.

• Ensure public confidence in the approval or authorization process, safety, and efficacy of COVID-19 

vaccines.

• Help the public to understand key differences in FDA emergency use authorization and FDA approval

(i.e., licensure).

• Engage in dialogue with internal and external partners to understand their key considerations and needs 

related to COVID-19 vaccine program implementation.

• Ensure active, timely, accessible, and effective public health and safety messaging along with outreach 

to key state/local partners and the public about COVID-19 vaccines.

• Provide guidance to local health departments, clinicians, and other hosts of COVID-19 vaccination 

provider locations. 

• Track and monitor public receptiveness to COVID-19 vaccination messaging. 

Key Audiences

Messaging should be tailored for each audience to ensure communication is effective.

• Healthcare personnel (i.e., organizations and clinicians who will receive information about receiving and 

administering vaccine) 

• Health insurance issuers and plans (coverage for vaccine, in-network providers)

• Employers

• Government and community partners and stakeholders 

• Public/consumers

o Essential workers

o Those in groups at risk for severe outcomes from COVID-19 infection

o Those in groups at increased risk of acquiring or transmitting COVID-19 

o Those with limited access to vaccination services

Broad Communication Planning Phases

Messaging should be timely and applicable for the current phase of the COVID-19 Vaccination Program.

• Before vaccine is available

• Vaccine is available in limited supply for certain populations of early focus (Phase 1)
COVID-19 VACCINATION PROGRAM 

INTERIM PLAYBOOK FOR JURISDICTION

OPERATIONS – October 29, 2020

43 | Page Version 2.0

• Vaccine is increasing and available for other critical populations and the general public (Phase 2)

• Vaccine is widely available (Phase 3)

Communication Activities

• Communicate early about the safety of vaccines in general and have easily accessible, government 

information to address myths, questions, and concerns.

• Keep the public, public health partners, and healthcare providers well-informed about COVID-19 

vaccine(s) development, recommendations, and public health’s efforts.

• Engage and use a wide range of partners, collaborations, and communication and news media channels 

to achieve communication goals, understanding that channel preferences and credible sources vary 

among audiences and people at higher risk for severe illness and critical populations, and channels vary 

in their capacity to achieve different communication objectives.

• Communicate proactively whenever possible, anticipating issues and forecasting possible problems 

before they reach broad awareness.

• Ensure that communications meet the requirements of the Americans with Disabilities Act, the 

Rehabilitation Act, the Patient Protection and Affordable Care Act, the Plain Language Act, and other 

applicable disability rights laws for accessibility.

• Use information and education campaigns to extend reach and increase visibility of vaccine 

recommendations and resources.

• Work closely with partner agencies, representatives of local communities with critical populations, and 

intermediaries to achieve consensus on actions, consistency in messages, and coordinated 

communication activities.

• Communicate transparently about COVID-19 vaccine risks and recommendations, immunization 

recommendations, public health recommendations, and prevention measures.

Messaging Considerations

Public health messages and products should be tailored for each audience and developed with consideration for 

health equity. It is important to use plain language that is easily understood. Information should be presented in 

culturally responsive language and available in languages that represent the communities. Jurisdictions should 

be careful to address all people inclusively, with respect, using non-stigmatizing, bias-free language. Insufficient 

consideration of culture in developing materials may unintentionally result in misinformation, errors, confusion, 

or loss of credibility. When developing/utilizing materials, jurisdictions should check for the following: 

• Are there words, phrases, or images that could be offensive to or stereotypical of the cultural or 

religious traditions, practices, or beliefs of the intended audience? 

• Are there words, phrases, or images that may be confusing, misleading, or have a different meaning for 

the intended audience (e.g., if abstract images are used, will the audience interpret them as intended)?

• Are there images that do not reflect the look or lifestyle of the intended audience or the places where 

they live, work, or worship? 

• Are there health recommendations that may be inappropriate or prohibited for the social, economic, 

cultural, or religious context of the intended audience? 

• Are any toll-free numbers or reference web pages in the message in the language of the intended 

audience? 
COVID-19 VACCINATION PROGRAM 

INTERIM PLAYBOOK FOR JURISDICTION

OPERATIONS – October 29, 2020

44 | Page Version 2.0

These considerations and any others that emerge during message development and deployment should be 

reviewed again when material is translated.

Communication Channels

Even perfectly developed messages and materials will provide no benefit if they are not received by the 

intended audience. Jurisdictions and tribal organizations should explore how specific groups are most likely to 

access information with the communication methods available to them. Feedback mechanisms such as a web 

page or e-mail account to allow the audience to express concerns, ask questions, and request assistance are 

extremely important, and creating such mechanisms should be a priority for jurisdictions.

Traditional media channels 

• Print

• Radio

• TV

Digital media 

• Internet

• Social media

• Text messaging

Partners and Trusted Sources 

Working to engage and empower partners is critical to reinforcing COVID-19 vaccination messages. Efforts with 

partners and trusted sources should be integrated into other channels in addition to programmatic and 

community engagement efforts. These partners include:

• State and local government

• Employers

• Healthcare providers (including federally funded safety net and in-home care providers)

• Health insurance issuers and plans 

• Educators

• Unions and professional organizations

• Organizations serving minority populations and people with disabilities

• Community and faith-based groups

• Organizations serving tribal nations

Crisis and Risk Communication

Crisis and emergency risk communication (CERC) is the application of evidence-based principles to effectively 

communicate during emergencies. These principles are used by public health professionals and public 

information officers to provide information that helps people, stakeholders, and entire communities make the 

best possible decisions for themselves and their loved ones. CERC recognizes that during emergencies, we work 

under impossible time constraints and must accept the imperfect nature of our choices. 

CERC principles include:

• Be First

• Be Right 
COVID-19 VACCINATION PROGRAM 

INTERIM PLAYBOOK FOR JURISDICTION

OPERATIONS – October 29, 2020

45 | Page Version 2.0

• Be Credible

• Express Empathy

• Show Respect

Jurisdictions must have communication messaging before, during, and after COVID-19 vaccine is available to 

help communities understand the importance of vaccination as well as the benefits and risks. Communicating 

what is currently known, regularly updating this information, and continuing dialogue with media and other 

partners throughout the vaccine distribution and administration process is essential to establish and maintain 

trust and credibility.

Related Guidance and Reference Materials

Jurisdictions should regularly review available CDC COVID-19 Communication Resources. CDC has developed 

COVID-19 One-Stop Shop Toolkits for communication, including toolkits tailored for different populations as well 

as a social media toolkit. To reach essential workers for vaccination, jurisdictions may need to assist industry and 

businesses in communicating with employees about vaccination clinics. CDC’s COVID-19 Communications Plan 

for Select Non-Healthcare Critical Infrastructure Employers may be helpful for this purpose. 

CDC’s CERC manual is available online, including online trainings, and examples of how CERC is applied during 

emergencies, at https://emergency.cdc.gov/cerc/manual/index.asp.

The World Health Organization has developed a guide that provides strategies and tools to support effective 

communication planning and management in response to vaccine safety events. 
COVID-19 VACCINATION PROGRAM 

INTERIM PLAYBOOK FOR JURISDICTION

OPERATIONS – October 29, 2020

46 | Page Version 2.0

Section 13: Regulatory Considerations for COVID-19 

Vaccination

Initially available COVID-19 vaccines may be authorized for use under an EUA issued by FDA or approved as 

licensed vaccines. 

Emergency Use Authorization Fact Sheets

The EUA authority allows FDA to authorize either (a) the use of an unapproved medical product (e.g., drug, 

vaccine, or diagnostic device) or (b) the unapproved use of an approved medical product during an emergency 

based on certain criteria. The EUA will outline how the COVID-19 vaccine should be used and any conditions that 

must be met as requirements of authorized vaccine use. FDA will coordinate with CDC to confirm these 

“conditions of authorization.” Vaccine conditions of authorization are expected to include distribution 

requirements, reporting requirements, and safety and monitoring requirements. The EUA would be terminated

when either the HHS Secretary determines that circumstances justifying authorization of emergency use of the 

COVID-19 vaccine have ceased or there is a change in the approval status of the vaccine such that an EUA is no 

longer necessary. Additional information on EUAs, including guidance and frequently asked questions, is located 

on the FDA website.

Product-specific EUA fact sheets for COVID-19 vaccination providers will be made available that will include 

information on the specific vaccine product and instructions for its use. An EUA fact sheet for vaccine recipients 

will also be developed, and both will be made available on the FDA and CDC websites. Jurisdictions should 

ensure providers know where to find both the provider and recipient fact sheets, have read and understand 

them, and are clear on the requirement to provide the recipient fact sheet to each client/patient prior to 

administering vaccine.

Vaccine Information Statements

VISs are required by law for certain licensed vaccines and only if a vaccine is added to the Vaccine Injury 

Table. Optional VISs may be produced, but only after a vaccine has been licensed. Plans for developing a VIS for 

COVID-19 vaccine are not known at this time but will be communicated as additional information becomes 

available.

Additional information on VISs is located at https://www.cdc.gov/vaccines/hcp/vis/current-vis.html. 
COVID-19 VACCINATION PROGRAM 

INTERIM PLAYBOOK FOR JURISDICTION

OPERATIONS – October 29, 2020

47 | Page Version 2.0

Section 14: COVID-19 Vaccine Safety Monitoring

An “adverse event (AE) following immunization” is an adverse health problem or condition that happens after 

vaccination (i.e., a temporally associated event). It might be truly caused by the vaccine or it might be purely 

coincidental and not related to vaccination.

CDC continuously monitors the safety of vaccines given to children and adults in the United States. VAERS, coadministered by CDC and FDA, is the national frontline monitoring system for vaccine safety.

Vaccine Adverse Event Reporting System 

VAERS is a national early warning system to detect possible safety problems with vaccines. Anyone—a doctor, 

nurse, pharmacist, or any member of the general public—can submit a report to VAERS. VAERS is not designed 

to detect whether a vaccine caused an adverse event, but it can identify “signals” that might indicate possible 

safety problems requiring additional investigation.

Per the CDC COVID-19 Vaccination Program Provider Agreement, COVID-19 vaccination providers are required to 

report the following to VAERS:

• vaccine administration errors (whether associated with an AE or not), 

• serious AEs (even if they are not sure if the vaccination caused the event),

10

• multisystem inflammatory syndrome (MIS) in children or adults, and 

• cases of COVID-19 that result in hospitalization or death to VAERS. 

They are also required to report to VAERS any additional AEs and/or adhere to any revised safety reporting 

requirements per FDA’s conditions of authorized vaccine use posted on FDA’s website throughout the duration 

of the EUA, as applicable. Vaccination providers should also report any additional clinically significant adverse 

events following COVID-19 vaccination to VAERS, even if they are not sure if the vaccination caused the event. 

Jurisdictions should ensure that enrolled COVID-19 vaccination providers understand the procedures for 

reporting adverse events to VAERS. More information on submitting a VAERS report electronically can be found 

at https://vaers.hhs.gov/reportevent.html.

v-safe

CDC will implement v-safe, a new smartphone-based tool that uses text messaging and web surveys to check in 

with vaccinated individuals for adverse events after a COVID-19 vaccination. v-safe will also provide second-dose 

reminders (if needed) and live telephone follow up by CDC if vaccinated individuals report a medically significant 

event during a v-safe check-in. v-safe asks questions that help CDC monitor the safety of COVID-19 vaccines. 

Medically significant events will be identified if the vaccinated individual reports that they missed work, were 

unable to complete normal daily activities, or had to seek care from a health provider or healthcare professional. 

The information will be used to analyze common side effects (soreness in the arm, muscle aches, etc.) and to 

detect unexpected, serious health problems if they occur. 

10 Serious AEs are defined as: death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent 

or significant incapacity or substantial disruption of the ability to conduct normal life functions, a congenital anomaly/birth defect, or an 

important medical event that may not result in death, be life-threatening, or require hospitalization when, based upon appropriate 

medical judgment, it may jeopardize the individual and may require medical or surgical intervention to prevent one of the outcomes 

listed above. Serious AEs should be reported regardless of causality.
COVID-19 VACCINATION PROGRAM 

INTERIM PLAYBOOK FOR JURISDICTION

OPERATIONS – October 29, 2020

48 | Page Version 2.0

CDC will create a v-safe information sheet that contains background on the v-safe program and instructions for

enrolling. Healthcare professionals and healthcare facilities that are giving COVID-19 vaccines are asked to

provide printed hard copies of the v-safe information sheet to each vaccinated individual and counsel them on 

the importance of enrolling in v-safe. The v-safe information sheet and counseling script are in development and 

will be made available electronically when competed. It is critically important for vaccine safety monitoring and 

assessment that healthcare professionals give each patient a v-safe information sheet at the time of vaccination 

and encourage patients to enroll. 

The following two vaccine safety monitoring programs require no actions from jurisdictions, but descriptions are 

provided for informational purposes to help in fielding questions about COVID-19 vaccine safety monitoring.

Vaccine Safety Datalink

The Vaccine Safety Datalink (VSD) is a collaboration between CDC’s Immunization Safety Office and nine 

healthcare organizations. This active surveillance system monitors electronic health data on vaccination and 

medical illnesses diagnosed in various healthcare settings and conducts vaccine safety studies based on 

questions or concerns raised from medical literature and findings from VAERS monitoring.

Clinical Immunization Safety Assessment Project

CDC’s Clinical Immunization Safety Assessment (CISA) Project is a national network of vaccine safety experts 

from CDC’s Immunization Safety Office and seven medical research centers. This project conducts clinical 

research, assesses complex events following vaccination, and provides consultations to U.S. healthcare providers 

and public health partners. 

Healthcare providers or health departments in the United States can request a consultation from CISA for a 

complex COVID-19 vaccine safety question that is (1) about an individual patient residing in the United States or 

vaccine safety issue and (2) not readily addressed by Centers for Disease Control and Prevention (CDC) or 

Advisory Committee on Immunization Practices (ACIP) guidelines. CISA consultations can be requested by calling 

CDC-INFO at 800-CDC-INFO (800-232-4636) or using the CDC-INFO webform. Please indicate that the request is 

for a CISA evaluation. The request will be forwarded to the CISA Project clinicians for review.
COVID-19 VACCINATION PROGRAM 

INTERIM PLAYBOOK FOR JURISDICTION

OPERATIONS – October 29, 2020

49 | Page Version 2.0

Section 15: COVID-19 Vaccination Program Monitoring

Continuous monitoring for situational awareness throughout the COVID-19 Vaccination Program is crucial for a 

successful outcome. Prior to receiving COVID-19 vaccine, jurisdictions should establish procedures for 

monitoring various critical program planning and implementation elements, including performance targets, 

resources, staffing, and activities. 

CDC Dashboards

To provide situational awareness for jurisdictions and the general public throughout the COVID-19 vaccination 

response, two dashboards will be available. 

CDC’s Weekly Flu Vaccination Dashboard will include weekly estimates of influenza vaccination for adults, 

children, and pregnant women using existing (National Immunization Survey [NIS]-Flu) data sources. Data and 

estimates from additional sources will be added, as available. 

An additional dashboard, the Operation Warp Speed (OWS) Tiberius platform, is a COVID-19 vaccine distribution 

planning, tracking, modeling, and analysis application that provides flexible, real-time, data-backed processes so 

users of all types can make data-driven decisions. Tiberius will integrate data sources from federal agencies, 

state and local partners, private-sector partners, and other data providers to create a comprehensive common 

operating picture for the COVID-19 vaccine planning, distribution, and administration effort that awardees can 

use to support the COVID-19 vaccine response. Awardees can reach out to their OWS point of contact or POB 

project officer to request access.

Resources

Jurisdictions and tribal nations should regularly monitor their resources to avoid unexpected obstacles to the 

progress of their COVID-19 Vaccination Programs. 

Staffing

Having enough adequately trained staff with current situational awareness is key to a successful COVID19 Vaccination Program. Specialized expertise is required, and it is important to have backups in each 

specialty area to guard against interruption of activities because of illness or other personal situations. 

For example, if staff are supporting temporary or off-site COVID-19 vaccination clinics, the hours are 

likely to be long and physically taxing. Managers and supervisors need to regularly check in with and 

support assigned staff’s wellness and overall resilience to perform the assigned tasks.

Inventory

Important activities during the COVID-19 Vaccination Program might be halted if certain supplies are 

depleted without replenishment. Jurisdictions may find it helpful to develop lists and track inventory for 

various program components (e.g., temporary/off-site clinics, vaccination provider enrollment and 

training, vaccine management). Regular monitoring of such records will foster early prompts to order 

and replenish supplies and ensure availability as needed. For example, jurisdictions will need to project 

and monitor use of PPE throughout the response and have ordering and procurement protocols in place 

for securing additional supplies.
COVID-19 VACCINATION PROGRAM 

INTERIM PLAYBOOK FOR JURISDICTION

OPERATIONS – October 29, 2020

50 | Page Version 2.0

Messaging

CDC will provide timely messaging throughout the COVID-19 vaccination response via all-jurisdiction calls, 

regular e-mail communication, and website updates. Jurisdictions and Tribal Nations should routinely monitor 

both CDC and local-level messaging to inform their communications efforts. Variations in messaging can create 

confusion and hamper the effective implementation of the vaccination program. Messaging must be clear, 

current, and received as intended by the audience. Monitoring social media can be helpful in assessing message 

delivery and reception and dispelling inaccurate information.

Local Jurisdictions

Constant communication and coordination with local jurisdictions and Tribal Nations are instrumental during all 

phases of the COVID-19 Vaccination Program in both centralized and decentralized operational structures. Long 

before the vaccination program begins, roles and responsibilities should be established and well understood at 

all levels. This will help avoid misperceptions as well as gaps in planning and implementation. Throughout the 

COVID-19 Vaccination Program, jurisdictions should monitor and maintain awareness of local-level strategies 

and activities, providing technical assistance as needed. This visibility can help ensure local jurisdictions and 

providers adhere to recommendations and guidance from CDC and state, local, and tribal authorities.
51 | Page Version 2.0

Appendix A: COVID-19 Vaccination Planning Assumptions 

for Jurisdictions (revised 10/29/2020)

Many COVID-19 vaccine candidates are in development, and clinical trials are being conducted simultaneously 

with large-scale manufacturing. It is not known which vaccines may be authorized or approved for use by FDA or 

when such EUA authorizations or approvals will take place. COVID-19 Vaccination Program plans must be 

flexible and accommodate multiple scenarios. For the purpose of initial planning, consider the following 

assumptions. 

COVID-19 VACCINE 

• Limited COVID-19 vaccine doses may be available by mid November 2020 if a COVID-19 vaccine is 

authorized or licensed by FDA by that time, but COVID-19 vaccine supply may increase substantially in 2021. 

• Initially available COVID-19 vaccines are anticipated to be authorized for use under Emergency Use 

Authorization (EUA) issued by the U.S. Food and Drug Administration. 

• Cold chain storage and handling requirements for each COVID-19 vaccine product will vary from 

refrigerated (2°C to 8°C) to frozen (-15°C to -25°C) to ultra-cold (-60°C to -80°C) temperatures, and ongoing 

stability testing may impact these requirements. Note: These temperatures are based on information 

available as of October 29, 2020. Updated information will be provided as it becomes available. 

• Jurisdictions should develop strategies to ensure the correct match of COVID-19 vaccine products and 

dosing intervals. Once authorized or approved by the FDA, two doses of COVID-19 vaccine, separated by 

either 21 or 28 days, will be needed for most COVID-19 vaccine products, and second-dose reminders for 

patients will be necessary. Both doses will need to match each other (i.e., be the same vaccine product). 

• Some COVID-19 vaccine products will likely require mixing with diluent at the point of administration. 

COVID-19 VACCINE ALLOCATION 

• Final decisions are being made about use of initially available supplies of COVID-19 vaccines. These 

decisions will be partially informed by the proven efficacy of the vaccines coming out of Phase 3 trials, but 

populations of focus for initial COVID-19 vaccination may include: 

o

o

o

o

o

o

o

Healthcare personnel (paid and unpaid people serving in healthcare settings who have the 

potential for direct or indirect exposure to patients or infectious materials and are unable to work 

from home) 

Non-healthcare essential workers

Adults with underlying medical conditions that are risk factors for severe COVID-19 illness 

People 65 years of age or older

• Allocation of COVID-19 vaccine to jurisdictions will be based on multiple factors, including: 

Critical populations recommended by the Advisory Committee on Immunization Practices (with 

input from the National Academies of Sciences, Engineering, and Medicine) 

Current local spread/prevalence of COVID-19

COVID-19 vaccine production and availability 

• Jurisdictions should anticipate that allocations may shift during the response based on supply, demand, 

and risk. 

• Each jurisdiction should plan for high-demand and low-demand scenarios. 
52 | Page Version 2.0

COVID-19 VACCINATION PROVIDER OUTREACH AND ENROLLMENT 

• To receive and administer COVID-19 vaccine and ancillary supplies, vaccination providers must enroll in 

the federal government (USG) COVID-19 Vaccination Program, coordinated through their jurisdiction’s 

immunization program, by signing and agreeing to conditions outlined in the CDC COVID-19 Vaccination 

Program Provider Agreement. 

• CDC will make this agreement available to each jurisdiction’s immunization program for use in 

conducting outreach and enrolling vaccination providers. Jurisdictions will be required to maintain these 

agreements on file for a minimum of 3 years. 

• Jurisdictions will be required to collect and submit to CDC information on each enrolled vaccination 

provider/site, including provider type and setting, patient population (i.e., number and type of patients 

served), refrigerated/frozen/ultra-cold temperature storage capacity, and logistical information for receiving 

COVID-19 vaccine shipments. 

• Some multijurisdictional vaccination providers (e.g., select retail pharmacy chains, the Indian Health 

Service, other federal entities) will enroll directly with CDC to order and receive COVID-19 vaccine. These 

direct partners will be required to report vaccine supply and uptake information back to each respective 

jurisdiction. CDC will share additional information when available on these procedures to ensure 

jurisdictions have full visibility for planning and documentation purposes. 

• Jurisdictions may choose to partner with commercial entities to reach the initial populations of focus. 

• Routine immunization programs will continue. 

COVID-19 VACCINE ORDERING AND DISTRIBUTION 

• COVID-19 vaccine and ancillary supplies will be procured and distributed by the federal government at 

no cost to enrolled COVID-19 vaccination providers. CDC will share more information about reimbursement 

claims for administration fees as it becomes available. 

• CDC will use its current centralized distribution contract to fulfill orders for most COVID-19 vaccine 

products as approved by jurisdiction immunization programs. Some vaccine products, such as those with 

ultra-cold temperature requirements, will be shipped directly from the manufacturer. 

• Jurisdiction-enrolled vaccination providers will follow the jurisdiction’s vaccine ordering procedures. 

• COVID-19 vaccination providers will be required to report COVID-19 vaccine inventory each time a 

COVID-19 vaccine order is placed. 

• Vaccine orders will be approved and transmitted in CDC’s Vaccine Tracking System (VTrckS) by 

jurisdiction immunization programs for vaccination providers they enroll. 

• Vaccine (and diluent, if required) will be shipped to provider sites within 48 hours of order approval by 

the immunization program, if supply is available. Ancillary supply kits and diluent (if required) will ship 

separately from the vaccine due to different cold chain requirements, but shipment will be timed to arrive 

with or before the vaccine. 

• Ancillary supply kits will include needles, syringes, alcohol prep pads, COVID-19 vaccination record cards 

for each vaccine recipient, and a minimal supply of personal protective equipment (PPE), including surgical 

masks and face shields, for vaccinators. 

o

o

Each kit will include supplies needed to administer 100 doses of vaccine. 

Jurisdictions may need to plan for additional PPE, depending on vaccination site needs. 
53 | Page Version 2.0

o For COVID-19 vaccines that require mixing with diluent at the point of administration, these 

ancillary supply kits will include additional necessary syringes, needles, and other supplies for this 

purpose. 

o Sharps containers, gloves, bandages, and other supplies will not be included. 

• Minimum order size for CDC centrally distributed vaccines will be 100 doses per order for most vaccines. 

Minimum order size for direct-ship vaccines will be 975 doses. CDC will provide more detail as it becomes 

available. 

• Vaccine will be sent directly to vaccination provider locations for administration or designated depots 

for secondary distribution to administration sites (e.g., chain drugstores’ central distribution). 

• Once vaccine products have been shipped to a provider site, the federal government will not 

redistribute product. 

• Jurisdictions will be allowed to redistribute vaccines while maintaining the cold chain. However, with the 

challenge of meeting cold chain requirements for frozen or ultra-cold vaccines, jurisdictions should be 

judicious in their use of redistribution and limit any redistribution to refrigerated vaccines only. 

• Jurisdictions are not advised to purchase ultra-cold storage equipment at this time. Ultra-cold vaccine 

may be shipped from the manufacturer in coolers that are packed with dry ice. These coolers should be 

repacked with dry ice within 24 hours of receipt of shipment (day 0) and repacked again every 5 days to 

maintain required temperature. On day 15, the vaccine should be moved into the refrigerator, stored at 2°C

to 8°C, and used within 5 days (120 hours). 

 

To be determined: 

• Vaccine disposal/recovery procedures 

COVID-19 VACCINE ADMINISTRATION DATA REPORTING 

• Jurisdictions will be required to report CDC-defined data elements related to vaccine administration 

daily (i.e., every 24 hours). CDC will provide information on these data elements to jurisdictions. 

• All vaccination providers may be required to report and maintain their COVID-19 vaccination inventory

information in CDC’s VaccineFinder daily. 

• CDC has prioritized jurisdiction onboarding to the Immunization (IZ) Gateway* to allow Immunization 

Information Systems (IISs) to receive data directly from national providers, nontraditional vaccination 

providers, and other external systems, as well as to report vaccine administration data to CDC. 

• Data Use Agreements (DUAs) will be required for data sharing via the IZ Gateway and other methods of 

vaccine administration data sharing with CDC and will be coordinated by each jurisdiction’s immunization 

program. 

COMMUNICATION 

• CDC will develop communication resources for jurisdictions and tribal organizations to use with key 

audiences. These resources will be available on a public-facing website currently under development, but 

jurisdictions and tribal organizations will likely need to tailor messaging and resources specific to special 

populations in their communities. 

• CDC will work with national organizations to disseminate key messages. 

• Communication and educational materials about COVID-19 vaccination provider enrollment, COVID-19 

vaccine ordering, COVID-19 vaccine storage, handling, administration (i.e., mixing with diluent, 

administration techniques), etc. will be available in a variety of formats. 
54 | Page Version 2.0

• When vaccine supply is available for expanded groups among the general population, a national COVID19 vaccine finder will be available on the public-facing VaccineFinder. 

• A screening tool on the CDC website will help people determine their own eligibility for COVID-19 

vaccine and direct them to VaccineFinder. 

 

COVID-19 VACCINE SAFETY 

• Vaccine safety monitoring is required under the EUA(s) for COVID-19 vaccine. Select adverse events are 

required to be reported to the Vaccine Adverse Event Reporting System (VAERS) (i.e., vaccine administration 

errors, serious adverse events, multisystem inflammatory syndrome (MIS) in children or adults, and cases of 

COVID-19 that result in hospitalization or death). Any revised safety reporting requirements should also be 

adhered to. FDA’s EUA website containing letter(s) of authorization and fact sheets should be checked for

any updates that may occur. 

• Any additional clinically significant adverse events following vaccination should be reported to the 

VAERS. 

• Adverse events will also be monitored through electronic health record- and claims-based systems (e.g., 

Vaccine Safety Datalink). 

* The IZ Gateway is a portfolio of project components that share a common IT infrastructure. The IZ Gateway aims to rapidly 

onboard IISs to support readiness for COVID-19 vaccine response through data exchange, both among IIS and between IIS 

and federal providers, mass vaccination reporting, and consumer access tools. The IZ Gateway aims to increase the 

availability and volume of complete and accurate immunization data stored within IIS and available to providers and 

consumers regardless of their jurisdictional boundaries.
55 | Page Version 2.0

Appendix B: COVID-19 Vaccination Scenarios for 

Jurisdictional Planning—Phase 1, Q4 2020 (updated 10/29/2020)

The planning scenarios described below should be used by state and local jurisdictions to develop operation plans for 

early COVID-19 vaccination when vaccine supply may be constrained. The scenarios describe potential COVID-19 

vaccine requirements, early supply estimates in the event that a vaccine is authorized under EUA, and populations 

that may be recommended for vaccination during this early period. These scenarios are designed to support 

jurisdictional, federal, and partner planning, but they are still considered hypothetical. The COVID-19 vaccine 

landscape is evolving and uncertain, and these scenarios may change as more information is available. 

Planners should assume that by January 2021, significantly more COVID-19 vaccine may be available for distribution 

and plans will need to evolve to address additional vaccine availability. Please refer to COVID-19 vaccine planning 

assumptions and additional guidance from the Centers for Disease Control and Prevention. 

Scenario 1: FDA has authorized vaccine A for Emergency Use Authorization 

(EUA) in 2020

Availability Assumptions 

Vaccine availability under EUA by

Candidate End of Nov 2020 End of Dec 2020 Notes

Vaccine A 10M–20M doses 20M–30M 

doses 

Ultra-cold (-70°C) storage 

requirements, for large sites only 

Distribution, Storage, Handling, and Administration Assumptions 

Vaccine A

SHIPMENT 

3 separately acquired components (mixed 

on site) 

1. Vaccine 

• 2 mL multidose vials (5 doses/vial)

• Direct to site from manufacturer (on 

dry ice) in thermal shipping container 

• Thermal shipper estimated specs: 400

mm X 400 mm X 560 mm, (15.75” X

15.75” X 22.0”)

• Each shipper can hold up to 5 trays, 

and each tray will hold up to 195 vials.

• Tray (i.e., “pizza box”) estimated 

specs: 229 mm X 229 mm X 40 mm

(9” X 9” X 1.6”)

2. Diluent and ancillary supply kits (for 

administration and mixing)

• Direct to site from the federal

government (at room temperature) 

3. Thermal shipper should be returned after

use. Instructions for mail-back and labels 

will be forthcoming.

ON-SITE VACCINE STORAGE 

Ultra-Cold Temp Frozen (-60°C to -80°C)

• Freezer units capable of ultra-cold temperatures (UCTs)

• The shipping container (thermal shipper) may be used to store 

vaccines: 

o Once received (day 1), the thermal shipper should be 

replenished with pelleted dry ice within 24 hours.

o Shippers should be replenished with dry ice every 5 days

thereafter to maintain required temperature.

o Total amount of dry ice needed per thermal shipper 

“recharge” is ~23 kg. 

o On day 15, transfer the vaccine to refrigerated temperatures 

(2–8°C). Use within 5 days (120 hours).

o Shippers may only be opened two times a day.

• Temperature monitoring must be in alignment with CDC 

guidance, irrespective of re-icing.

o Thermal shipper may be monitored using a temperature 

probe on the container, in alignment with guidance provided 

by CDC and information provided by the manufacturer. 

o Direct handling of dry ice needed for recharging the 

containers will require the use of appropriate PPE.

Thawed but NOT diluted (2°C to 8°C) 
56 | Page Version 2.0

• Product may be removed from ultra-cold storage or thermal 

shipper, thawed, and stored at 2°C–8°C for up to 5 days (discard 

unused doses after 5 days).

• Cannot return to ultra-cold storage or thermal shipper once 

thawed 

Diluted (room temperature) 

• If removed directly from ultra-cold temperatures, vaccine must be 

thawed ~30 minutes at room temperature before dilution. 

• Once vaccine is thawed, it must be diluted within 2 hours. If 

unable to dilute within 2 hours, store at 2°C–8°C.

• Must use diluted vaccine within 6 hours (discard any unused, 

diluted vaccine after 6 hours)

ORDERS 

Large quantities, to large provider sites only 

• Minimum order: ~1,000 doses 

• Maximum order: ~5,000 doses 

ADMINISTRATION 

2-dose series (21 days between doses) 

• On-site mixing required; dilute with diluent just prior to 

administration; all 5 doses must be administered within 6 hours of 

dilution; remainder of diluted vaccine should be discarded.

• Administer by intramuscular (IM) injection.

INITIAL POPULATIONS OF FOCUS AND ANTICIPATED VACCINATION PROVIDER SITES 

NOTE: Primary vaccination provider sites may consider providing vials to other sites. HOWEVER, all cold chain 

requirements should be maintained and logged in accordance with the information provided above.

Healthcare personnel — public health clinics, closed points of dispensing (PODs), temporary/off-site vaccination clinics + 

potential for mobile clinics

Other essential workers — public health clinics, closed PODs, temporary/off-site vaccination clinics + potential for mobile 

clinics

Adults with underlying medical conditions and people 65 years of age and older — open PODs in strategic locations, 

potential for mobile clinics at long-term care facilities (LTCFs) or partnership with pharmacy on-site clinics for LTCFs, 

correctional/detention facilities, and other congregate settings

Additional Considerations for Early Vaccination Planning 

• “Healthcare personnel” includes paid or unpaid persons serving in healthcare settings who have the potential 

for direct or indirect exposure to people with COVID-19 or infectious materials.

• Jurisdictions should plan for real-time shipment of doses.

• Vaccination provider sites (during Phase 1) will not be required to store vaccine products beyond the period of 

time. Vaccine A can be stored in the ultra-cold thermal shipper or at refrigerated temp (2°C–8°C, see “Thawed 

but NOT diluted” section). 

• Given the challenging storage, handling, and administration requirements, early vaccination should focus on 

vaccination provider sites that can reach critical populations with as much throughput as possible. 

• Stability testing is ongoing for Vaccine A; the storage and handling requirements presented here may shift. The 

requirements in these scenarios are likely the strictest set of requirements for which planning is needed. 

• Jurisdictions should consider partnering with the private sector and with local hospital systems to provide 

vaccine in closest proximity to the critical populations as possible, given vaccine product storage and handling 

requirements. For example, Vaccine A may be administered by mobile clinics if multiple mobile clinics are 

planned over a short period of time to ensure sufficiently high throughput. Vaccine A may also be placed in 

healthcare systems and support multiple clinics in one system (where product can be shared and repositioned 

from one site to another at 2°C–8°C). 

• Ensure equitable access for adults with underlying medical conditions and people 65 years of age and older 

who are part of other critical populations. Additional vaccination provider sites may be required to reach these 

populations.
57 | Page Version 2.0

Scenario 2: FDA has authorized vaccine B for EUA in 2020 

Availability Assumptions 

Vaccine availability under EUA by

Candidate End of Nov 2020 End of Dec 2020 Notes

Vaccine B ~10M doses ~15M doses Central distributor capacity required 

(-20°C) 

Distribution, Storage, Handling, and Administration Assumptions 

Vaccine B

SHIPMENT ON-SITE VACCINE STORAGE 

2 separately shipped components 

Vaccine 

• To central distributor (at -20°C) 

• Multidose vials (10 doses/vial) 

Ancillary supply kits 

• Direct to site from USG (at room temperature)

Frozen (-25°C to -15°C until ready for use)

Note: This is a narrower range than for varicella-containing 

vaccines.

Refrigerated (2°C to 8°C) 

• Must use within 7 days if the vial has not been entered 

• Thaw before use: 

• Thaw in refrigerated conditions between 2°C to 8°C 

for 2 hours. Let vial stand at room temperature for 

15 minutes before administering. 

• Alternatively, thaw at room temperature between 

20°C to 25°C for 1 hour. 

• After thawing, do not return vial to the freezer.

Room temperature 

• The total time between removal from refrigeration and 

administration should be no more than 12 hours.

• Once the vial has been entered, it must be used within 

6 hours (discard any unused vaccine after 6 hours).

ORDERS 

Central distribution capacity 

• Required by Dec 2020 

• Maintained at -20°C 

ADMINISTRATION 

2-dose series (1 month between doses) 

• No on-site mixing required

• Once thawed, swirl vaccine gently prior to withdrawing 

a dose. Do NOT shake.

• Administer by intramuscular (IM) injection.

INITIAL POPULATIONS OF FOCUS AND ANTICIPATED VACCINATION PROVIDER SITES 

Healthcare personnel — healthcare clinics + healthcare occupational health clinics + public health clinics, closed PODs, 

temporary/off-site vaccination clinics + mobile clinics

Other essential workers (specifics TBA) — occupational health clinics + hospital clinics + public health clinics, closed 

PODs, temporary/off-site vaccination clinics

Adults with underlying medical conditions and people 65 years of age and older — commercial pharmacy partners 

+ mobile clinics
58 | Page Version 2.0

Additional Considerations for Early Vaccination Planning 

• “Healthcare personnel” includes paid or unpaid persons serving in healthcare settings who have the potential 

for direct or indirect exposure to people with COVID-19 or infectious materials.

• Jurisdictions should plan for real-time shipment of doses.

• Administration sites (during Phase 1) will not be required to store vaccine products beyond the period of time 

Vaccine B can be stored at 2–8°C. 

• Given the challenging storage, handling, and administration requirements, early vaccination should focus on 

administration sites that can reach critical populations with as much throughput as possible. 

• Stability testing is ongoing for Vaccine B; the storage and handling requirements presented here may shift. The 

requirements in these scenarios are likely the strictest set of requirements for which planning is needed. 

• Jurisdictions should consider partnering with the private sector and with local hospital systems to provide 

vaccine in closest proximity to the prioritized populations as possible, given limitations with the product. 

• Ensure equitable access for adults with underlying medical conditions and people 65 years of age and older 

who are part of other critical populations. Additional vaccination provider sites may be required to reach these 

populations.
59 | Page Version 2.0

Scenario 3: FDA has authorized vaccines A and B for EUA in 2020 

Availability Assumptions 

Vaccine availability under EUA by

Candidate End of Nov 2020 End of Dec 2020 Notes

Vaccine A 10M–20M doses 20M–30M doses Ultra-cold (-70°C), for large sites only 

Vaccine B ~10M doses ~15M doses Central distribution capacity required 

(-20°C) 

Total 20M–30M doses 35M–45M doses 

Distribution, Storage, Handling, and Administration Assumptions 

Vaccine A

SHIPMENT 

3 separately acquired components (mixed on site) 

1. Vaccine 

• 2 mL multidose vials (5 doses/vial)

• Direct to site from manufacturer (on dry ice) in 

thermal shipping container 

• Thermal shipper estimated specs: 400 mm X 

400 mm X 560 mm (15.75” X 15.75” X 22.0”)

• Each shipper can hold up to 5 trays, and each 

tray will hold up to 195 vials.

• Tray (i.e., “pizza box”) estimated specs: 229 mm 

X 229 mm X 40 mm (9” X 9” X 1.6”) 

2. Diluent and ancillary supply kits (for administration 

and mixing)

• Direct to site from the federal government (at 

room temperature) 

3. Thermal shipper should be returned after use. 

Instructions for mail-back and labels will be 

forthcoming.

ON-SITE VACCINE STORAGE 

Ultra-Cold Temp Frozen (-60°C to -80°C)

• Freezer units capable of ultra-cold temperatures (UCTs)

• The shipping container (thermal shipper) may be used 

to store vaccines: 

o Once received (day 1), the thermal shipper should 

be replenished with pelleted dry ice within 24 

hours.

o Shippers should be replenished with dry ice every 

5 days thereafter to maintain required 

temperature.

o Total amount of dry ice needed per thermal 

shipper “recharge” is ~23 kg. 

o On day 15, transfer the vaccine to refrigerated 

temperatures (2°C to 8°C). Use within 5 days (120 

hours).

o Shippers may only be opened two times a day.

• Temperature monitoring must be in alignment with 

CDC guidance, irrespective of re-icing.

o Thermal shipper may be monitored using a 

temperature probe on the container, in alignment 

with guidance provided by CDC and information 

provided by the manufacturer. 

o Direct handling of dry ice needed for re-icing the 

containers will require the use of appropriate PPE.

Thawed but NOT diluted (2°C to 8°C) 

• Product may be removed from the ultra-cold storage or 

thermal shipper, thawed, and stored at 2°C to 8°C for 

up to 5 days (discard unused doses after 5 days).

• Cannot return to ultra-cold storage or thermal shipper 

once thawed 
60 | Page Version 2.0

Diluted (room temperature) 

• If removed directly from ultra-cold storage, vaccine 

must be thawed ~30 minutes at room temperature 

before dilution. 

• Once vaccine is thawed, it must be diluted within 2 

hours. If unable to dilute within 2 hours, store at 2°C–

8°C.

• Must use diluted vaccine within 6 hours (discard any 

unused diluted vaccine after 6 hours)

ORDERS 

Large quantities, to large provider sites only 

Minimum order: ~1,000 doses 

Maximum order: ~5,000 doses

ADMINISTRATION 

2-dose series (21 days between doses) 

• On-site mixing required; dilute with diluent just prior to 

administration; all 5 doses must be administered within 

6 hours of dilution; remainder of diluted vaccine should 

be discarded.

• Administer by IM injection.

PRIORITIZED POPULATIONS AND ANTICIPATED VACCINATION PROVIDER SITES 

Healthcare personnel — public health clinics, closed PODs, temporary/off-site vaccination clinics + potential for mobile 

clinics

Other essential workers (specifics TBA) — public health clinics, closed PODs, temporary/off-site vaccination clinics + 

potential for mobile clinics 

Adults with underlying medical conditions and people 65 years of age and older — commercial pharmacy partners, 

open PODs in strategic locations, potential for mobile clinics at LTCFs, correctional/detention facilities, and other 

congregate settings

Vaccine B

SHIPMENT ON-SITE VACCINE STORAGE 

2 separately shipped components 

Vaccine 

• To central distributor (at -20°C) 

• Multidose vials (10 doses/vial) 

Ancillary supply kits 

• Direct to site from USG (at room temperature)

Frozen (-25°C to15°C until ready for use)

Note: This is a narrower range than for varicella-containing 

vaccines.

Refrigerated (2°C to 8°C) 

• Must use within 7 days if the vial has not been entered.

• Thaw before use: 

• Thaw in refrigerated conditions between 2°C to 8°C 

for 2 hours. Let vial stand at room temperature for 

15 minutes before administering. 

• Alternatively, thaw at room temperature between 

20°C to 25°C for 1 hour. 

• After thawing, do not return vial to the freezer.

Room temperature 

• The total time before administration and after removal 

from the refrigerator should be no more than 12 hours.

• Once the vial has been entered, it must be used within 

6 hours (discard any unused vaccine after 6 hours).
61 | Page Version 2.0

ORDERS 

Central distribution capacity 

• Required by Dec 2020 

• Maintained at -20°C 

ADMINISTRATION 

2-dose series (1 month between doses) 

• No on-site mixing required

• Once thawed, swirl vaccine gently prior to withdrawing 

a dose. Do NOT shake.

• Administer by intramuscular (IM) injection

INITIAL POPULATIONS OF FOCUS AND ANTICIPATED VACCINATION PROVIDER SITES 

Healthcare personnel — healthcare clinics + healthcare occupational health clinics + public health clinics, closed PODs, 

temporary/off-site vaccination clinics + mobile clinics

Other essential workers (specifics TBA) —occupational health clinics + hospital clinics + public health clinics, closed 

PODs, temporary/off-site vaccination clinics

Adults with underlying medical conditions and people 65 years of age and older — commercial pharmacy partners 

+ mobile clinics

Additional Considerations for Early Vaccination Planning 

• “Healthcare personnel” includes paid or unpaid persons serving in healthcare settings who have the potential 

for direct or indirect exposure to people with COVID-19 or infectious materials. 

• Jurisdictions should plan for real-time shipment of doses. 

• Administration sites (during Phase 1) will not be required to store vaccine products beyond the period of time 

Vaccine A can be stored in the ultra-cold shipment box or Vaccine B can be stored at 2–8°C.

• Given the challenging storage, handling, and administration requirements, early vaccination should focus on 

administration sites that can reach prioritized populations with as much throughput as possible. 

• Stability testing is ongoing for Vaccine A and Vaccine B; the storage and handling requirements presented here 

may shift. The requirements in these scenarios are likely the strictest set of requirements for which planning is 

needed. 

• Jurisdictions should consider partnering with the private sector and with local hospital systems to provide 

vaccine in closest proximity to the prioritized populations as possible, given the limitations with the product. 

For example: Vaccine A may be administered through mobile clinics if multiple mobile clinics are planned over 

a short period of time to ensure sufficiently high throughput. 

• Ensure equitable access for adults with underlying medical conditions and people 65 years of age and older 

who are part of other critical populations. Additional vaccination provider sites may be required to reach these 

populations.
62 | Page Version 2.0

Appendix C: Phase 1 Population Group Worksheet Example

Sub-Group Agency/Organization Point of Contact 

(POC) POC Number Contact e-mail Key Group

Estimate 

# in Key 

Group

Long-Term 

Care

Town Nursing Home Jane Smith 123-456-7899 townnh@gmail.com Direct Care Staff 50

County Nursing Home John White 123-789-1234 conursinghome@co.gov Direct Care Staff 50

Hospitals

ABC Hospital Joe Admin 123-555-6666 jadmin@abchosp.com ICU Staff 50

Direct Care Staff 200

City X Hospital Sue Jones 123-666-5555 cityx@hospital.com Direct Care Staff 300

Public Health

Anywhere Health Dept. Ann Stewart 123-222-1234 astewart@cohd.gov Clinic Staff 50

Staff Providing Direct Care 40

Other 

Healthcare 

Essential 

Workers

County Emergency Services Sam Stone 123-555-9876 sstone@coems.gov Ambulance Staff 25

Medical Reserve Corp Mike Reserve 123-777-8888 mrcmike@mrc.com Clinic Volunteers 30

PHASE 1-A POPULATION GROUP: HEALTHCARE PERSONNEL
63 | Page Version 2.0

Appendix D: CDC IIS Data Requirements for COVID-19 

Vaccine Monitoring

CDC IIS DATA REQUIREMENTS FOR COVID-19 VACCINE ADMINISTRATION

BACKGROUND AND PURPOSE

The ongoing, rapid monitoring of COVID-19 vaccine uptake will be a critical part of the nation’s COVID19 response efforts. Immunization programs and immunization information systems (IIS) will play a 

critical role in vaccine delivery, the monitoring of vaccine doses administered, and generation of 

vaccination coverage estimates among several different population groups. 

A strong, nationally coordinated approach is critical to collecting, tracking, and analyzing vaccination 

data, especially in early phases of vaccine administration, which is expected to occur in non-traditional 

settings. This document outlines the anticipated vaccine administration data elements IIS will report to 

CDC. The required data elements in this document represent demographic and vaccination information 

routinely captured by an IIS during a vaccination event. In addition to the ability to collect and report 

these data elements, IIS will also be required to report information from these data elements 1) in a 

timely fashion (within 24 hours of administration) and 2) through a connection to the Immunization 

Gateway (IZ Gateway) or data lake. This will enable CDC to reliably track COVID-19 vaccinations and 

analyze vaccination coverage by demographic factors once vaccine supplies are available. The vaccine 

administration data elements in this document will continue to evolve to include inventory and 

distribution elements as those parameters are finalized.

DISCRETE DATA ELEMENTS

Table 1 includes each data element that IIS will be required to report to CDC. Table 2 includes each 

data element that will be optional for IIS to report to CDC. Optional data requirements will support 

additional national coverage analysis and vaccination monitoring efforts. Data elements are also 

categorized as “Mass Vaccination” or “Standard.” Standard data elements are likely already collected 

by IIS, whereas Mass Vaccination data elements are likely to require enhancements or a Mass 

Vaccination module for data collection and reporting. Any identifiable data elements will be used to 

facilitate deduplication of data within the Immunization Data Lake, an analytic environment that will 

be used to consolidate, deduplicate, and reconcile vaccine administration information from multiple 

sources (e.g. jurisdictional immunization programs, pharmacies, Department of Defense, Veterans 

Affairs, Bureau of Prisons, Indian Health Service). Identifiable elements will not be stored in the Data 

Lake environment.

Table 1. Required Data Elements 

Required Data Element Mass Vaccination or Standard

Data elements required for IIS to report Mass Vaccination = may require mass vaccination module 

or enhancement

Standard = IIS Core Data Element commonly collected 

during routine vaccination 

Administered at location: facility name/ID Standard

Administered at location: type Standard

Administration address (including county) Standard

Administration date Standard

CVX (Product) Standard
64 | Page Version 2.0

Dose number Standard

Recipient race Standard

Recipient ethnicity Standard

IIS recipient ID* Standard

IIS vaccination event ID Standard

Lot number: unit of use and/or unit of sale Standard

MVX (manufacturer) Standard

Recipient address* Standard

Recipient date of birth* Standard

Recipient name* Standard

Recipient sex Standard

Sending organization Standard

Vaccine administering provider suffix Standard

Vaccine administering site (on the body) Standard

Vaccine expiration date Standard

Vaccine route of administration Standard

Vaccination series complete Mass Vaccination

*Identifiable information

Table 2. Optional Data Elements 

Optional Data Element Mass Vaccination or Standard

Data elements optional for IIS to report (e.g., state 

mass vaccination tool collects this information)

Mass Vaccination = may require mass vaccination module 

or enhancement

Standard = IIS Core Data Element commonly collected 

during routine vaccination

Comorbidity status (Y/N) Mass Vaccination

Recipient missed vaccination appointment (Y/N) Mass Vaccination

Serology results (Presence of Positive Result, Y/N) Mass Vaccination

Vaccination Refusal (Y/N) Standard

*Identifiable Information
65 | Page Version 2.0

Appendix E: Countermeasures Injury Compensation 

Program

The Public Readiness and Emergency Preparedness Act (PREP Act) authorizes the Countermeasures Injury 

Compensation Program (CICP) to provide benefits to certain individuals or estates of individuals who sustain a 

covered serious physical injury as the direct result of the administration or use of covered countermeasures 

identified in and administered or used under a PREP Act declaration. The CICP also may provide benefits to 

certain survivors of individuals who die as a direct result of the administration or use of such covered 

countermeasures. The PREP Act declaration for medical countermeasures against COVID-19 states that the 

covered countermeasures are:

• Any antiviral, any other drug, any biologic, any diagnostic, any other device, any respiratory protective 

device, or any vaccine, used:

o To treat, diagnose, cure, prevent, mitigate, or limit the harm from COVID-19, or the transmission of 

SARS-CoV-2 or a virus mutating therefrom, or

o To limit the harm that COVID-19, or the transmission of SARS-CoV-2 or a virus mutating therefrom, 

might otherwise cause; or

• Any device used in the administration of any such product, and all components and constituent materials of 

any such product.

Covered Countermeasures must be ''qualified pandemic or epidemic products,'' or ''security countermeasures,'' 

or drugs, biological products, or devices authorized for investigational or emergency use, as those terms are 

defined in the PREP Act, the Federal Food, Drug, and Cosmetic Act (FD&C Act), and the Public Health Service Act, 

or a respiratory protective device approved by National Institute for Occupational Safety and Health (NIOSH) 

under 42 CFR part 84, or any successor regulations, that the Secretary of the Department of Health and Human 

Services determines to be a priority for use during a public health emergency declared under section 319 of the 

Public Health Service Act.

For more information about the CICP, visit the program’s website at www.hrsa.gov/cicp, email cicp@hrsa.gov, 

or call 1-855-266-CICP (1-855-266-2427).
66 | Page Version 2.0

Appendix F: Liability Immunity for Covered Persons

The Declaration Under the Public Readiness and Emergency Preparedness Act (PREP Act) for Medical 

Countermeasures Against COVID-19 provides liability immunity to covered persons. The third amendment to the 

declaration defines “covered persons” as follows:

“V. Covered Persons 

42 U.S.C. 247d–6d(i)(2), (3), (4), (6), (8)(A) and (B) 

Covered Persons who are afforded liability immunity under this Declaration are ‘‘manufacturers,’’ 

‘‘distributors,’’ ‘‘program planners,’’ ‘‘qualified persons,’’ and their officials, agents, and employees, as 

those terms are defined in the PREP Act, and the United States. 

In addition, I [the Secretary] have determined that the following additional persons are qualified 

persons: 

(a) Any person authorized in accordance with the public health and medical emergency 

response of the Authority Having Jurisdiction to prescribe, administer, deliver, distribute or 

dispense the Covered Countermeasures, and their officials, agents, employees, contractors and 

volunteers, following a Declaration of an emergency; 

(b) any person authorized to prescribe, administer, or dispense the Covered Countermeasures 

or who is otherwise authorized to perform an activity under an Emergency Use Authorization in 

accordance with Section 564 of the FD&C Act; 

(c) any person authorized to prescribe, administer, or dispense Covered Countermeasures in 

accordance with Section 564A of the FD&C Act; and 

(d) a State-licensed pharmacist who orders and administers, and pharmacy interns who 

administer (if the pharmacy intern acts under the supervision of such pharmacist and the 

pharmacy intern is licensed or registered by his or her State board of pharmacy), vaccines that

the Advisory Committee on Immunization Practices (ACIP) recommends to persons ages three 

through 18 according to ACIP’s standard immunization schedule. 

Such State-licensed pharmacists and the State-licensed or registered interns under their supervision are 

qualified persons only if the following requirements are met: 

• The vaccine must be FDA authorized or FDA-approved. 

• The vaccination must be ordered and administered according to ACIP’s standard immunization 

schedule. 
67 | Page Version 2.0

• The licensed pharmacist must complete a practical training program of at least 20 hours that is 

approved by the Accreditation Council for Pharmacy Education (ACPE). This training program 

must include hands-on injection technique, clinical evaluation of indications and 

contraindications of vaccines, and the recognition and treatment of emergency reactions to 

vaccines. 

• The licensed or registered pharmacy intern must complete a practical training program that is 

approved by the ACPE. This training program must include hands-on injection technique, clinical 

evaluation of indications and contraindications of vaccines, and the recognition and treatment 

of emergency reactions to vaccines. 

• The licensed pharmacist and licensed or registered pharmacy intern must have a current 

certificate in basic cardiopulmonary resuscitation. 

• The licensed pharmacist must complete a minimum of two hours of ACPE-approved, 

immunization-related continuing pharmacy education during each State licensing period. 

• The licensed pharmacist must comply with recordkeeping and reporting requirements of the 

jurisdiction in which he or she administers vaccines, including informing the patient’s primarycare provider when available, submitting the required immunization information to the State or 

local immunization information system (vaccine registry), complying with requirements with 

respect to reporting adverse events, and complying with requirements whereby the person 

administering a vaccine must review the vaccine registry or other vaccination records prior to 

administering a vaccine. 

• The licensed pharmacist must inform his or her childhood-vaccination patients and the adult 

caregiver accompanying the child of the importance of a well-child visit with a pediatrician or 

other licensed primary care provider and refer patients as appropriate. 

Nothing in this Declaration shall be construed to affect the National Vaccine Injury Compensation 

Program, including an injured party’s ability to obtain compensation under that program. Covered 

countermeasures that are subject to the National Vaccine Injury Compensation Program authorized 

under 42 U.S.C. 300aa–10 et seq. are covered under this Declaration for the purposes of liability 

immunity and injury compensation only to the extent that injury compensation is not provided under 

that Program. All other terms and conditions of the Declaration apply to such covered 

countermeasures.”
68 | Page Version 2.0

Appendix G: Vaccination Implementation Strategies to Consider for Critical Populations

(New)

Vaccinating the critical infrastructure workforce, people at increased risk for severe COVID-19 illness, people at increased risk of acquiring or transmitting 

COVID-19, and people with limited access to routine vaccination services may be challenging for several reasons. Various strategies, some with 

commonality across groups and others unique to certain populations, should be considered to reach these critical populations for COVID-19 vaccination. 

Provider 

Recruitment and 

Enrollment

• Communicate vaccination provider requirements and enrollment procedures widely throughout jurisdiction, including to all 

long-term care and correctional/detention facilities.

• Enroll a variety of providers throughout jurisdiction, especially those serving critical populations, such as:

o Health departments

o Health clinics (including federally qualified health centers and community health centers)

o Health Care for Homeless clinics

o Physicians’ offices

o Hospitals (emergency departments)

o Home healthcare providers

o Employers/occupational health clinics

o College/university health services/clinics that serve young adults

o Pharmacies

o Long-term care facilities

o Correctional/detention facilities

o Mobile clinics

o Points of dispensing (PODs)

Enumerating and 

Locating 

Populations

• Map distribution of critical populations or the facilities/locations they live or work in (e.g., long-term care facilities, 

correctional/detention facilities, homeless shelters or encampments, colleges, and universities).

• Map location of enrolled providers and their capacity.

• Compile and maintain critical points of contact for reaching critical populations, for example:

o Large healthcare systems operating within the jurisdiction 

o Large retail pharmacies serving people within the jurisdiction

o Large employers of critical workers within the jurisdiction

o Home healthcare providers

o Long-term care facilities

o Correctional/detention facilities

o College and university presidents
69 | Page Version 2.0

o Tribal leaders and local Indian Health Service administrators

o Homeless shelters, soup kitchens, syringe service programs, and Continuum of Care Homeless Assistance programs

o Intermediate care facilities, group homes, and paratransit services for people with disabilities

• Utilize electronic health records or administrative data for estimating critical population size/location (e.g., CMS, trade group 

databases, point-in-time estimates and housing inventory count data, college/university student enrollment records).

Vaccine 

Administration

• Ensure social distancing, mask use, and/or other preventive measures by enrolled providers.

• Encourage vaccination providers to schedule clinic visits to prevent congregation of individuals.

• Consider utilizing risk-specific vaccination options/events (e.g., events specifically and only for people ≥65 years of age).

• Consider establishing institutional standing orders where possible.

• Ensure consent is obtained ahead of time if medical proxy is in place.

• For people living in institutions, consider vaccinating at intake; for people attending colleges/universities, vaccinate at 

enrollment.

• Engage community members from the critical populations for planning (e.g., people with disabilities).

• Engage trusted sources to educate about vaccine recommendations and availability and to address hesitancy. For example:

o Professional organizations, state licensure boards, and healthcare coalitions

o Critical workforce employers and union representatives

o Specific critical populations health advocacy organizations

o College/university presidents, athletic coaches, and other student/campus organizations

o Homeless shelter/soup kitchen/syringe service program managers

o Social workers

o Faith leaders

• Ensure vaccination clinics are available during different times of day/evening to accommodate different schedules.

• Conduct mobile clinics in multiple locations at non-traditional sites, such as:

o Small health clinics not enrolled as providers

o Intermediate care facilities and group homes for people with disabilities

o Long-term care facilities

o Correctional/detention facilities

o Employers and job fairs

o College/university parking lots, gyms, dining halls, faculty buildings, and residence halls

o Homeless shelters, soup kitchens, syringe service programs, homeless encampments

o Faith-based organizations

o Public libraries, public parks

o Community fairs

• Leverage ongoing seasonal influenza vaccination clinics.
70 | Page Version 2.0

Second-Dose 

Reminders

• Use a variety of methods to send second-dose reminders to recipients and/or medical proxies, including:

o Vaccination cards

o Electronic health records/patient portals

o Text messaging

o Phone calls

o Email

o Mail

o Peer navigators/mentors

• For people living in institutions who are moved after receipt of first dose, link them to vaccination providers in the 

community or send reminders to the receiving facility.

Documentation 

and Reporting

• Provide training to qualified vaccination providers on use of the jurisdiction’s immunization information system (IIS) or other 

external tracking system.

• Leverage various other administrative systems, as able (e.g., employer systems, Homeless Management Information system).

Provider/ 

Administrator 

Communications

• Educate healthcare providers throughout jurisdiction about recommendations to vaccinate critical populations and, if not an 

enrolled provider, where to refer patients for free vaccination.

• Educate nonclinical facility administrators about recommendations to vaccinate critical populations, such as:

o Employer human resource staff

o Correctional/detention facility wardens, leadership, and health services

o College/university administrators, faculty, and staff

o Homeless shelter staff

• Ensure providers have information needed on vaccine recommendations to counsel patients, including relevant 

contraindications or potential lower efficacy in certain groups.

• For people in institutions, train providers to ensure transfer of vaccination records to receiving facility or request vaccination

records from previous facility.

• Message directly to caretakers, medical proxies, or parents of college/university students to encourage uptake.

Critical 

Population 

Communications

• Develop diverse communication materials on vaccine recommendations and where to get vaccinated for people in critical 

population groups, such as:

o Flyers/posters at:

 Healthcare provider facilities (e.g., physicians’ offices, health centers, hospital emergency departments)

 Large employers

 Pharmacies

 Long-term care facilities
71 | Page Version 2.0

 Correctional/detention facilities

 College/university campuses

 Homeless shelters, homeless encampments, soup kitchens, syringe service programs

 Retail stores

 Bus stations

 Public parks and libraries

o Newspaper (print and online) advertisements

o Online/social media advertisements, including on advocacy organization websites

o Mail/postcards

o Population-specific communications (e.g., employer communications, trade magazines, senior-focused publications, 

college/university newspapers, or other communications)

• Ensure all communication materials are culturally and linguistically appropriate, including messaging with American Sign 

Language, large print, and braille.

• Create low-literacy messages, including those for people with severe intellectual disabilities.

• Ensure all messaging complies with ADA regulations.
72 | Page Version 2.0

Appendix H: Pharmacy Partnership for Long-Term Care 

Program for COVID-19 Vaccination (New)

HHS is partnering with CVS and Walgreens to offer on-site COVID-19 vaccination services for residents

of nursing homes and assisted living facilities once vaccination is recommended for them.

The Pharmacy Partnership for Long-term Care (LTC) Program provides end-to-end management of the COVID19 vaccination process, including cold chain management, on-site vaccinations, and fulfillment of reporting 

requirements, to facilitate safe vaccination of this patient population, while reducing burden on LTC facilities 

and jurisdictional health departments. LTCF staff who have not received COVID-19 vaccine can also be 

vaccinated as part of the program. This program provides critical vaccination services and is free of charge to 

facilities. This effort will require extensive coordination with jurisdictions, long-term care facilities (LTCFs), 

federal partners, including the Centers for Medicare and Medicaid Services (CMS), and professional 

organizations, including American Health Care Association (AHCA) and Leading Age, which include members 

across both nursing homes and assisted living facilities.

As part of this program, which is free of charge to facilities, the pharmacy will:

• Schedule and coordinate on-site clinic date(s) directly with each facility. Three visits over 

approximately two months will likely be needed to administer both doses of vaccine and vaccinate 

any new residents and staff.

• Order vaccines and associated supplies (e.g., syringes, needles, personal protective equipment).

• Ensure cold chain management for vaccine.

• Provide on-site administration of vaccine.

• Report required vaccination data (approximately 20 data fields) to the local, state/territorial, and 

federal jurisdictions within 72 hours of administering each dose.

• Adhere to all applicable Centers for Medicare & Medicaid (CMS) COVID-19 testing requirements for 

LTCF staff.

If interested in participating, LTCFs should sign up (or opt out) starting October 19. Sign up will remain open for 

two weeks.

• Skilled nursing facilities (SNFs) will make their selection through the National Healthcare Safety 

Network (NHSN). An “alert” will be incorporated into the NHSN LTCF COVID-19 module to guide 

users to the form.

• Assisted living facilities (ALFs) will make their selection via an online

REDCap (https://redcap.link/LTCF) sign-up form.

• Facilities will indicate which pharmacy partner (one of two large retail pharmacies or existing LTC 

pharmacy) they prefer to have on site.

• Online sign-up information will be distributed through ALF and SNF partner communication channels 

(email, social media, web).

• Indicating interest in participating is non-binding and facilities may change their selection or opt in 

or out via email after the online survey closes.

Once the sign-up period has closed, no changes can be made via the online form, and the facility must 

coordinate directly with the selected pharmacy provider to change any requested vaccination supplies and 

services.

HHS will communicate preferences to CVS and Walgreens and will try to honor facility preferences but may 

reassign facilities depending on vaccine availability and distribution considerations and to minimize vaccine 

wastage.
73 | Page Version 2.0

HHS expects the program services to continue on site at participating facilities for approximately two 

months. After the initial phase of vaccinations, each facility can choose to continue working with CVS or 

Walgreens or can work with a pharmacy provider of its choice.

For questions about the Pharmacy Partnership for Long-term Care Program, please 

contact eocevent494@cdc.gov.
74 | Page Version 2.0

Appendix I: Federal Pharmacy Partnership for COVID-19 

Vaccination Program (New)

HHS is partnering with pharmacies to increase access to COVID-19 vaccine once a vaccine is authorized or 

approved and recommended for use in the United States. Through the Federal Pharmacy Partnership Strategy 

for COVID-19 Vaccination, select pharmacy partners will receive a direct allocation of COVID-19 

vaccine. This will help jurisdictions augment access to vaccine when supply increases and vaccine is 

recommended beyond the initial critical populations. With more than 86% of people living within five miles of a 

community pharmacy, pharmacies have unique reach and ability to provide access to COVID-19 

vaccine and support broad vaccination efforts. This program will provide critical vaccination services for 

the U.S. population, with vaccine administered at retail locations at no cost to recipients. The program will be 

implemented in close coordination with jurisdictions to ensure optimal COVID-19 vaccination coverage and 

vaccine access nationwide. 

The federal allocation to pharmacies will not cover every pharmacy in the United States. Pharmacies not 

included in the federal allocation program are still encouraged to be part of the vaccination program and should 

coordinate with their jurisdictions to become COVID-19 vaccination providers.

Program Benefits

Once we have an adequate supply of COVID-19 vaccine to support broader vaccination efforts, it will be 

important to swiftly increase access to COVID-19 vaccine for the general population (Phase 2, COVID –19 

implementation planning). Partnerships with retail chain pharmacies and networks of community pharmacists in 

the United States will increase the general population’s access to COVID-19 vaccine.

Pharmacists can be crucial public health partners to increase access and convenience of COVID-19 vaccines.

• Pharmacists are trained to provide vaccinations and are important immunizers in their communities. 

• Pharmacists are a trusted health resource in their communities and play a vital role in the public health 

response to COVID-19 by counseling patients and administering tests. 

• Pharmacies have the capability to quickly surge and meet demand nationwide because of existing 

infrastructure and the large number of pharmacists who can administer vaccines.

• CDC has worked extensively with pharmacy chains to improve pandemic preparedness, conduct vaccine 

throughput exercises, and assess store and organizational response capabilities.

Program Participants 

Retail chain pharmacies and networks of community pharmacists are being considered for this program. As of 

Monday, October 29, the following pharmacy partners have signed on to participate in this program:

• Walgreens

• CVS Health Corporation

• Walmart Stores, Inc (including Sam’s)

• Rite Aid Corp

• The Kroger Co (i.e., Kroger, Harris Teeter, Fred Meyer, Frys, Ralphs, King Soopers, Smiths, City Market, 

Dillons, Marianos, Pick-n-Save, Copps, Metro Market)

• Publix

• Costco
75 | Page Version 2.0

• Albertsons Companies (i.e., Osco, Jewel-Osco, Albertsons, Albertsons Market, Safeway, Tom Thumb, 

Star Market, Shaws, Haggen, Acme, Randalls, Carrs, Market Street, United, Vons, Pavilions, Amigos, 

Lucky’s, Pak n Save, Sav-On)

• Hy-Vee

• Meijer

• H-E-B

• Retail Business Services (i.e., Food Lion, Giant Food, The Giant Company, Hannaford Bros Co, Stop & 

Shop)

Together, these pharmacy partners will extend the COVID-19 vaccination provider network to over 35,000 store 

locations. Store lists for each of these partners will be shared with jurisdictions. Additional partners are also

expected to sign on, further expanding the program. Details on additional partners will be shared with 

jurisdictions as soon as they are available. 

Based on their (1) size and reach, (2) capability to store vaccines and ensure cold chain management, (3) ability 

to meet data reporting requirements to jurisdictions and CDC, and (4) estimated daily number of doses each 

facility is able to administer, these partners stand ready to assist jurisdictions in COVID-19 vaccination efforts.

Program Implementation

Pharmacy partners must sign a COVID-19 pharmacy partner agreement to participate.  Before receiving COVID19 vaccine, the partner must propose, in writing, its minimum capacity for vaccine administration, including a) 

the number and location of facilities that will administer COVID-19 vaccine, b) the estimated number of COVID19 vaccine doses that each facility will be able to administer within defined periods, and c) estimated cold chain 

storage capacity.

• Pharmacy partners will directly order and receive allocation of COVID-19 vaccine from the federal 

government.

• Vaccine will be provided at no cost to the pharmacy chain and will be administered at retail locations at 

no cost to vaccine recipients.

• On a daily basis, pharmacy partners must report to CDC the number of doses of COVID-19 vaccine a) 

ordered by store location in VTrcks and b) on hand in each store reported through VaccineFinder. 

Pharmacy providers will also be required to report CDC-defined data elements related to vaccine 

administration to jurisdiction IISs or through other agreed upon methods (e.g., formatted data extracts) 

to jurisdictions if IIS reporting is not available. 

• Pharmacy partners will provide a point of contact for reach jurisdiction for questions related to 

allocation of vaccine in store locations in their jurisdiction area.

• Jurisdictions may choose to opt out of having pharmacies in their area receive allocations through this 

program.

For questions about the Federal Pharmacy Partnership Strategy for COVID-19 Vaccination Program, please 

contact eocevent481@cdc.gov.